CUMULATIVE
SUPPLEMENT 9
JAN'98-SEP'98



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

1998

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 9

SEPTEMBER 1998

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 9
SEPTEMBER 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA MERCK INC (ASTRA MERCK)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
ASTRA USA INC (ASTRA)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
DUPONT RADIOPHARMACEUTICALS DIV (DUPONT)	DUPONT PHARMACEUTICALS COMPANY (DUPONT PHARMS)
FUJISAWA USA INC (FUJISAWA)	AMERICAN PHARMACEUTICAL PARTNERS INC (AM PHARM PARTNERS)
JONES MEDICAL INDUSTRIES INC (JONES MEDCL INDS)	JONES PHARMA INC (JONES PHARMA)

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet. There is more than one media users may select to access these files.

Preface and ASCII Text Files:
The Preface may be accessed using this URL: http://www.fda.gov/cder/orange/adp.htm. Users who wish to download the Prescription Drug Product List; OTC Drug Products and Discontinued Drug Products lists may access the ASCII text files using this URL: htttp://www.fda.gov/cder/orange/obreadme.htm. The drug product lists and the zipobtxt.exe files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and B are updated twice a year.

Preface and Searchable Query Database:
The Preface may be accessed using this URL: http://www.fda.gov/cder/ob/docs/preface/ectablec18.htm. Users who wish to query on a specific drug product may access the database using this URL: http://www.fda.gov/cder/ob. The Query enables searching of the database by active ingredient, proprietary name, applicant holder or applicant number. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	MAR 1998	JUN 1998	SEP 1998
DRUG PRODUCTS LISTED	9624	9711	9768	9798
SINGLE SOURCE	2462 (25.6%)	2484 (25.6%)	2494 (25.6%)	2479 (25.3%)
MULTISOURCE	7052 (73.3%)	7117 (73.3%)	7164 (73.3%)	7208 (73.6%)
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6746 (69.5%)	6790 (69.5%)	6829 (69.7%)
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	371 (3.8%)	374 (3.8%)	379 (3.9%)
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	8	9	4
NUMBER OF APPLICANTS	551	529	538	551

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACARBOSE

TABLET; ORAL

PRECOSE

	#	BAYER	25MG	N20482 004 MAY 29, 1997	
			25MG	N20482 004 MAY 29, 1997	> DLT >
					> DLT >
					> DLT >
					> ADD >
					> ADD >

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

> DLT >	AB		DANBURY PHARMA	325MG;50MG	N87550 001 OCT 19, 1984
> DLT >					
> ADD >		#		325MG;50MG	N87550 001 OCT 19, 1984
> ADD >					

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	AB		MALLINCKRODT	325MG;50MG;40MG	N87804 001 JAN 24, 1985
	AB	◆	MIKART	500MG;50MG;40MG	N89451 001 MAY 23, 1988
	AB		WATSON LABS	500MG;50MG;40MG	N40267 001 JUL 30, 1998
			SEPAR		
	AB		MALLINCKRODT	325MG;50MG;40MG	N87804 001 JAN 24, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA		ROXANE LABS	300MG;15MG	[illegible]
	AA			300MG;20MG	[illegible]
	AA			300MG;60MG	[illegible]
	AA		WATSON LABS	300MG;15MG	DEC 28, 1994
	AA			300MG;30MG	N89998 001 DEC 28, 1994

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA		WATSON LABS	300MG;60MG	N89999 001 DEC 28, 1994
					> DLT >
					> DLT >
					> DLT >
					> ADD >
					> ADD >

ACETAMINOPHEN AND CODEINE PHOSPHATE #1

	AA		BURNEAC PHARM	300MG;15MG	N89080 001 JUL 17, 1986
		#		300MG;30MG	N89080 001 JUL 17, 1986

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	◆	MIKART	500MG/15ML;7.5MG/15ML	N81051 001 AUG 28, 1992
	AA		PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001 MAR 13, 1998

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

> ADD >	AA		ENDO PHARMS	500MG;5MG	N40281 001 SEP 30, 1998
> ADD >	AA			500MG;7.5MG	N40280 001 SEP 30, 1998
> ADD >	AA			650MG;7.5MG	N40280 002 SEP 30, 1998
> ADD >	AA			650MG;10MG	N40280 003 SEP 30, 1998
> ADD >	AA			750MG;7.5MG	N40281 002 SEP 30, 1998
> ADD >	AA		MALLINCKRODT	500MG;7.5MG	N40201 001 FEB 27, 1998
> ADD >	AA			500MG;10MG	N40201 002 FEB 27, 1998
	AA		ROXANE LABS	500MG;5MG	[illegible]
	AA			500MG;7.5MG	[illegible]
	AA			500MG;7.5MG	[illegible]
	AA			650MG;7.5MG	[illegible]
	AA			650MG;10MG	[illegible]

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	BOYCE LABS	325MG;7.5MG	N40122 002 MAR 04, 1996	
AA	WATSON LABS	500MG;2.5MG	N40123 003 MAR 04, 1996	
AA		500MG;5MG	N40122 001 MAR 04, 1996	
AA		500MG;7.5MG	N40123 004 MAR 04, 1996	
AA		650MG;7.5MG	N40123 001 MAR 04, 1996	
AA		650MG;10MG	N40123 002 MAR 04, 1996	
AA		750MG;7.5MG	N40122 002 MAR 04, 1996	

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	HALSEY	500MG;5MG	N40219 001 JAN 22, 1998	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;5MG	N40257 001 AUG 04, 1998	
AA	BOYCE LABS	325MG;5MG	N40234 001 OCT 30, 1997	
AA	WATSON LABS	500MG;5MG	N40234 001 OCT 30, 1997	

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	DURAMED	325MG;5MG	N40272 001 JUN 30, 1998	
AA	BOYCE LABS	325MG;5MG	N40171 001 OCT 30, 1997	
AA	WATSON LABS	325MG;5MG	N40171 001 OCT 30, 1997	

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

AA	BOYCE LABS	650MG;65MG	N40139 001 DEC 16, 1996	
AA	WATSON LABS	650MG;65MG	N40139 001 DEC 16, 1996	

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	B BRAUN	250MG/100ML	N18161 001	
AT	MCGAW	250MG/100ML	N18161 001	

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	CHELSEA LABS	200MG	N75101 001 APR 15, 1998	
AB	GENPHARM	200MG	N74977 001 APR 13, 1998	
> ADD >				
AB	RANBAXY	200MG	N74975 001 SEP 30, 1998	
> ADD >				

TABLET; ORAL
ACYCLOVIR

AB	COPLEY PHARM	400MG	N75021 001 MAR 18, 1998	
AB		800MG	N75021 002 MAR 18, 1998	
AB	GENPHARM	400MG	N74976 001 APR 13, 1998	
AB		800MG	N74976 002 APR 13, 1998	
> ADD >				
AB	MYLAN	400MG	N75211 001 SEP 28, 1998	
> ADD >				
AB		800MG	N75211 002 SEP 28, 1998	
> ADD >				
*	NOVOPHARM	200MG	N74556 001 APR 22, 1997	
•		200MG	N74556 001 APR 22, 1997	
> ADD >				
AB	RANBAXY	400MG	N74980 001 SEP 30, 1998	
> ADD >				

ACYCLOVIR

TABLET; ORAL
ACYCLOVIR

> ADD >	AB	RANBAXY	800MG	N74980 002 SEP 30, 1998
> ADD				

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001 APR 30, 1998
+	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998
AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001 FEB 27, 1998
AP		EQ 1GM BASE/VIAL	N74897 002 FEB 27, 1998
AP	[redacted]	[redacted]	[redacted]

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD

+	FUJISAWA HLTHCARE	3MG/ML	N19937 002 OCT 30, 1989
[redacted]	[redacted]	[redacted]	[redacted]

ADENOSCAN

+	FUJISAWA HLTHCARE	3MG/ML	N20059 001 MAY 18, 1995
[redacted]	[redacted]	[redacted]	[redacted]

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	BAUSCH AND LOMB	EQ 0.5% BASE	N75050 001 JUN 18, 1998
AN	HI TECH PHARMA	EQ 0.5% BASE	N74543 001 JAN 15, 1998

ALBUTEROL SULFATE

SYRUP; ORAL
ALBUTEROL SULFATE

AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001 JAN 30, 1998
AA	[redacted]	[redacted]	[redacted]
@		EQ 2MG BASE/5ML	N74302 001 SEP 30, 1994

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ZYLOPRIM

+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996
[redacted]	[redacted]	[redacted]	[redacted]

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	GENEVA PHARMS	2MG	N74909 001
AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	
AB		[redacted]	
AB	WATSON LABS	0.25MG	JAN 21, 1997
AB		0.5MG	N74479 002 JAN 21, 1997
AB		1MG	N74479 003 JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	BEDFORD	0.5MG/ML	N74815 001 JAN 20, 1998

PROSTIN VR PEDIATRIC

AP	+ PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001

ALPROSTADIL

INJECTABLE; INJECTION
PROSTIN VR PEDIATRIC
[redacted] PHARMACIA AND UPJOHN [redacted] [redacted]

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL
[redacted] [redacted] [redacted] [redacted]
AB + 100MG N70589 001 AUG 05, 1986

SYMMETREL
[redacted] [redacted] [redacted] [redacted]
● 100MG N16020 001

SYRUP; ORAL
SYMMETREL
[redacted] [redacted] [redacted] [redacted]
AA + ENDO PHARMS 50MG/5ML N16023 002

TABLET; ORAL
SYMMETREL
[redacted] [redacted] [redacted] [redacted]
+ 100MG N18101 001

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT
[redacted] [redacted] [redacted]
+ WYETH AYERST 0.1% N18498 001

AMILORIDE HYDROCHLORIDE

TABLET; ORAL
MIDAMOR
AB + MERCK 5MG N18200 001
[redacted] [redacted] [redacted] [redacted]

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE
[redacted] [redacted] EQ 5MG ANHYDROUS;50MG [redacted] [redacted]
AB WATSON LABS EQ 5MG ANHYDROUS;50MG N73334 001 JUL 19, 1991

MODURETIC 5-50
AB + MERCK EQ 5MG ANHYDROUS;50MG N18201 001
[redacted] [redacted] [redacted] [redacted] [redacted]

AMINO ACIDS

INJECTABLE; INJECTION
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 20% N20849 001 AUG 26, 1998

AMINOCAPROIC ACID

SYRUP; ORAL
AMICAR
> ADD > AA + IMMUNEX 1.25GM/5ML N15230 002
> DLT > [redacted] [redacted] [redacted]
> ADD > AMINOCAPROIC ACID
> ADD > AA MIKART 1.25GM/5ML N74759 001 SEP 02, 1998
> ADD >

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
CORDARONE
AB + WYETH AYERST 200MG N18972 001 DEC 24, 1985

PACERONE
AB UPSHER SMITH 200MG N75135 001 APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
> DLT > [redacted] [redacted] [redacted] [redacted]
> DLT > [redacted] [redacted]

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
[redacted]

> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> ADD >		●	10MG	[redacted]	N88620 001 MAR 02, 1984
> ADD >		●	25MG		N88621 001 MAR 02, 1984
> ADD >		●	50MG		N88622 001 MAR 02, 1984
> ADD >		●	75MG		N88633 001 MAR 02, 1984
> ADD >		●	100MG		N88634 001 MAR 02, 1984
> ADD >		●	150MG		N88635 001 MAR 02, 1984

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL
[redacted]

> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> DLT >	[redacted]	[redacted]			
> ADD >		●	10MG;2MG	[redacted]	FEB 15, 1989
> ADD >		●	10MG;4MG		N72540 001 FEB 15, 1989
> ADD >		●	25MG;2MG		N72541 001 FEB 15, 1989

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

> ADD >		● DANBURY PHARMA	25MG;4MG		N72134 001 FEB 15, 1989
> ADD >		●	50MG;4MG		N72135 001
> ADD >	[redacted]	[redacted]	[redacted]	[redacted]	
> ADD >	[redacted]	[redacted]	[redacted]		
> ADD >	[redacted]	[redacted]	[redacted]		
> ADD >	[redacted]	[redacted]	[redacted]		
> ADD >	AB	WATSON LABS	10MG;2MG		OCT 17, 1991
> ADD >	AB		10MG;4MG		N73009 001 OCT 17, 1991
> ADD >	AB		25MG;2MG		N73008 001 OCT 17, 1991
> ADD >	AB		25MG;4MG		N73010 001 OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%

	● B BRAUN	40MEQ/100ML		N85734 001
	[redacted]	[redacted]		[redacted]

AMOXICILLIN

TABLET; ORAL
AMOXIL

	+ SMITHKLINE BEECHAM	500MG		N50754 002 JUL 10, 1998
	+	875MG		N50754 001 JUL 10, 1998

AMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

AP	ABBOTT	EQ 5MG BASE/ML		N74616 001 AUG 03, 1998

AMRINONE LACTATE

INJECTABLE; INJECTION
INOCOR

AP	+ SANOFI	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

	[redacted]	[redacted]	[redacted]	
	+ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL,ASPIRIN,CAFFEINE AND CODEINE PHOSPHATE

AB	STEVENS J	325MG;50MG;40MG;30MG	N74951 001	AUG 31, 1998

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

AB	PAR PHARM	385MG;30MG;25MG	N75141 001	MAY 29, 1998

ORPHENGESIC FORTE

AB	PAR PHARM	770MG;60MG;50MG	N75141 002	MAY 29, 1998

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA	HALSEY	325MG;4.5MG;0.38MG	N40260 001	JUL 17, 1998
AA	WATSON LABS	325MG;4.5MG;0.38MG	N40255 001	FEB 27, 1998

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	GENPHARM	25MG	N74126 003	AUG 26, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB	MARTEC	50MG;25MG	N74404 001	MAY 14, 1998
AB		100MG;25MG	N74404 002	MAY 14, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

	[redacted]	[redacted]	[redacted]	
		[redacted]	[redacted]	
	[redacted]	[redacted]	[redacted]	
	WARNER LAMBERT EXPOR	EQ 10MG BASE	[redacted]	DEC 17, 1996
		EQ 20MG BASE	N20702 002	DEC 17, 1996
	+	EQ 40MG BASE	N20702 003	DEC 17, 1996

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	MARSAM	10MG/ML	N74945 001	JUL 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	MARSAM	10MG/ML	N74944 001	JUL 28, 1998

BACITRACIN

[redacted]

[redacted]					
[redacted]		[redacted]		[redacted]	
	●	5,000,000 UNITS/BOT		N62456 001	JUL 27, 1983

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

[redacted]		[redacted]		[redacted]	
AT	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002	

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOSPORIN

[redacted]		[redacted]		[redacted]	
AT	+	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

[redacted]		[redacted]		[redacted]	
AT		AKORN	500 UNITS/GM; 10,000 UNITS/GM	N64028 001	JAN 30, 1995

POLYSPORIN

[redacted]		[redacted]		[redacted]	
AT	+	MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM	N61229 001	

BACLOFEN

TABLET; ORAL

BACLOFEN

[redacted]		[redacted]		[redacted]	
AB		WATSON LABS	10MG	N73092 001	JAN 28, 1994
AB			20MG	N73093 001	JAN 28, 1994

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

VASCOR

[redacted]		[redacted]		[redacted]	
			300MG	N19002 002	DEC 28, 1990
	●		400MG	N19002 003	DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETAMETHASONE VALERATE

[redacted]		[redacted]		[redacted]	
	●		EQ 0.1% BASE	N70053 001	JUN 10, 1986

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

[redacted]		[redacted]		[redacted]		
	●		5MG	N84402 001	>DLT> >ADD>	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

>DLT>		BRETYLOL			
>DLT>	AP	* FAULDING	50MG/ML		N17954 001
>ADD>		●	50MG/ML		N17954 001

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

	AZOPT			
	+ ALCON	1%		N20816 001 APR 01, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL

	BROMOCRIPTINE MESYLATE			
AB	LEK PHARM	EQ 2.5MG BASE		N74631 001 JAN 13, 1998
	PARLODEL			
AB	+ NOVARTIS	EQ 2.5MG BASE		N17962 001

BROMPHENIRAMINE MALEATE

TABLET; ORAL

	BROMPHENIRAMINE MALEATE			
>DLT> AB	[redacted]	4MG		[redacted]
>ADD>	●	4MG		N83123 001

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ZYBAN			
	* GLAXO WELLCOME	100MG		[redacted]
	●	100MG		N20711 002 MAY 14, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE			
AP	BEDFORD	2MG/ML		N75046 001 AUG 12, 1998

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	BEDFORD	1MG/ML		N75045 001 AUG 12, 1998
AP		2MG/ML		N75045 002 AUG 12, 1998
>ADD> AP	FAULDING	1MG/ML		N75170 001 SEP 28, 1998
>ADD> AP		2MG/ML		N75170 002 SEP 28, 1998

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 80MG/100ML		N19864 001 JUN 10, 1993
	MCGAW	[redacted]		[redacted]

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

	ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML		N19867 001 DEC 20, 1993
	MCGAW	[redacted]		[redacted]

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER			
AP	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML		N18256 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML; 86MG/100ML N20000 001 APR 17, 1992

AP MCGAW [redacted]

AP [redacted]

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
● B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N17510 001

● MCGAW [redacted]

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML N19718 001 SEP 29, 1989

MCGAW [redacted]

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER
ABBOTT [redacted]

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION/CARDIAC
PLEGISOL IN PLASTIC CONTAINER
+ ABBOTT 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML;30MG/100ML; 86MG/100ML N18721 001 NOV 09, 1982

AP 33MG/100ML;30MG/100ML; 86MG/100ML N20002 001 APR 17, 1992

AP MCGAW [redacted]

AP [redacted]

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT B BRAUN 33MG/100ML;30MG/100ML; 86MG/100ML N18156 001

AT MCGAW [redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N19632 001 FEB 29, 1988

● 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18023 001

AP MCGAW [redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

	[redacted]	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	[redacted]		

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681 001 DEC 27, 1982		
AT	[redacted]	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	[redacted]		

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N20521 001 JUL 01, 1998		

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

	ASTRA MERCK	4MG	[redacted]		
		8MG	[redacted]		
		16MG	[redacted]		
§		32MG	[redacted]		
	ASTRA PHARMS	4MG	[redacted] JUN 04, 1998		
		8MG	N20838 002 JUN 04, 1998		
		16MG	N20838 003 JUN 04, 1998		
+		32MG	N20838 004 JUN 04, 1998		

CAPECITABINE

TABLET; ORAL
XELODA

	ROCHE	150MG	N20896 001 APR 30, 1998		
+		500MG	N20896 002 APR 30, 1998		

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

> DLT >	AB	[redacted]	12.5MG	[redacted]			
> DLT >							
> DLT >	AB		25MG				
> DLT >							
> DLT >	AB		50MG				
> DLT >							
> DLT >	AB		100MG				
> DLT >							
> ADD >		@	12.5MG	[redacted] MAR 31, 1997			
> ADD >		@	25MG	N74640 002 MAR 31, 1997			
> ADD >		@	50MG	N74640 003 MAR 31, 1997			
> ADD >		@	100MG	N74640 004			
> ADD >	AB	ROYCE LABS	12.5MG	[redacted]			
	AB		25MG	[redacted]			
	AB		50MG	[redacted]			
	AB		100MG	[redacted]			
	AB	WATSON LABS	12.5MG	N74451 001 FEB 13, 1996			
	AB		25MG	N74451 002 FEB 13, 1996			
	AB		50MG	N74451 003 FEB 13, 1996			
	AB		100MG	N74451 004 FEB 13, 1996			

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

AB		BRISTOL MYERS SQUIBB	25MG;15MG	N18709 001 OCT 12, 1984
AB		[redacted]	[redacted]	[redacted]

CAPOZIDE 25/25

AB	+	BRISTOL MYERS SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
AB	#	[redacted]	[redacted]	[redacted]

CAPOZIDE 50/15

AB	+	BRISTOL MYERS SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984
AB	#	[redacted]	[redacted]	[redacted]

CAPOZIDE 50/25

AB		BRISTOL MYERS SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984
AB		[redacted]	[redacted]	[redacted]

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB		ZENITH GOLDLINE	25MG;15MG	N75055 001 JUN 18, 1998
AB			25MG;25MG	N75055 002 JUN 18, 1998
AB			50MG;15MG	N75055 004 JUN 18, 1998
AB			50MG;25MG	N75055 003 JUN 18, 1998

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
	+	SHIRE	200MG	N20712 001 SEP 30, 1997
	+		300MG	N20712 002 SEP 30, 1997

CARBIDOPA

TABLET; ORAL

LODOSYN

[redacted]	#	[redacted]	[redacted]	[redacted]
	+	DUPONT PHARMS	25MG	N17830 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]	#		[redacted]	[redacted]
AB		DUPONT PHARMS	[redacted]	N17555 001
AB				N17555 003
AB	+			N17555 002

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

		[redacted]	[redacted]	[redacted]
	#		[redacted]	[redacted]
		DUPONT PHARMS	25MG;100MG	N19856 002 DEC 24, 1992
	+		50MG;200MG	N19856 001 MAY 30, 1991

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

[redacted]		[redacted]	[redacted]	[redacted]
AA		WATSON LABS	350MG	N40152 001 DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR

AB		MARSAM	EQ 125MG BASE/5ML	N64204 001 FEB 18, 1998
AB			EQ 187MG BASE/5ML	N64205 001 FEB 18, 1998

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL
CEFACLOR

AB	MARSAM	EQ 250MG BASE/5ML	N64206 001 FEB 18, 1998
AB		EQ 375MG BASE/5ML	N64207 001 FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	AM PHARM PARTNERS	EQ 1MG BASE/VIAL	N64169 002 AUG 14, 1998
AP		EQ 500MG BASE/VIAL	N64169 001 AUG 14, 1998
AP		EQ 10GM BASE/VIAL	N64170 001 MAR 18, 1998
AP		EQ 20GM BASE/VIAL	N64170 002 MAR 18, 1998

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

#	[redacted]	[redacted]	[redacted]
#		[redacted]	[redacted]
#		[redacted]	[redacted]
#		[redacted]	[redacted]
+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
+		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
+		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

#	[redacted]	[redacted]	[redacted]
●	FUJISAWA HLTHCARE	EQ 40MG BASE/ML	N50589 002 OCT 03, 1984

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX IN PLASTIC CONTAINER

#	[redacted]	[redacted]	[redacted]
#		[redacted]	[redacted]
+	FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003 APR 13, 1995
+		EQ 40MG BASE/ML	N50589 004 APR 13, 1995

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME

AB	ASTRA PHARMS	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP		EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998

CEFUROXIME SODIUM

>ADD>	AP	AM PHARM PARTNERS	EQ 7.5GM BASE/VIAL	N65002 001 SEP 28, 1998
>ADD>				

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	ZENITH GOLDLINE	EQ 250MG BASE	N61969 001
AB		EQ 500MG BASE	N61969 002
[redacted]	[redacted]	[redacted]	[redacted]

POWDER FOR RECONSTITUTION; ORAL
KEFLEX

#	[redacted]	[redacted]	[redacted]
●		EQ 100MG BASE/ML	N50406 003
+		EQ 100MG BASE/ML	N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL
CHLOROMYCETIN

[redacted]	*	[redacted]	[redacted]	[redacted]
	*		[redacted]	[redacted]
	*		[redacted]	[redacted]
AB	+	PARKEDALE	250MG	N60591 002
			50MG	N60591 001
	+		100MG	N60591 003

OINTMENT; OPHTHALMIC
CHLOROMYCETIN

[redacted]	*	[redacted]	[redacted]	[redacted]
AT	+	PARKEDALE	1%	N50156 001

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN

	*	[redacted]	[redacted]	[redacted]
	+	PARKEDALE	25MG/VIAL	N50143 001

SOLUTION/DROPS; OPHTHALMIC
OPHTHOCHLOR

[redacted]		[redacted]	[redacted]	[redacted]
AT		PARKEDALE	0.5%	N61220 001

SOLUTION/DROPS; OTIC
CHLOROMYCETIN

	*	[redacted]	[redacted]	[redacted]
	+	PARKEDALE	0.5%	N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE

	*	[redacted]	[redacted]	[redacted]
	+	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT

	*	[redacted]	[redacted]	[redacted]
			[redacted]	[redacted]
	*	PARKEDALE	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLOROMYCETIN

[redacted]	*	[redacted]	[redacted]	[redacted]
AP	+	PARKEDALE	EQ 1GM BASE/VIAL	N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

	+	ICN	5MG	N85482 001
	*		10MG	N85481 001
	*		25MG	N85488 001
	*	[redacted]	[redacted]	[redacted]
	*		[redacted]	[redacted]
	*		[redacted]	[redacted]

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
LIBRIUM

AB		ICN	5MG	N85461 001
AB			10MG	N85472 001
AB	+		25MG	N85475 001
[redacted]		[redacted]	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
[redacted]	*		[redacted]	[redacted]

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX

[redacted]	*	[redacted]	[redacted]	[redacted]
				AUG 13, 1986
AT	+	ZILA	0.12%	N19028 001
				AUG 13, 1986

TABLET; DENTAL
PERIOCHIP

	+	PERIO PRODS	2.5MG	N20774 001
				MAY 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HCL

>ADD>	AP	BEDFORD	2%	N40273 001 SEP 09, 1998		
>ADD>						
>ADD>	AP		3%	N40273 002 SEP 09, 1998		
>ADD>						

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

	+	MERCK	250MG/5ML	N11870 001		
	‡	[redacted]	[redacted]	[redacted]		

TABLET; ORAL

DIURIL

AB		MERCK	250MG	N11145 004		
AB	+		500MG	N11145 002		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		
[redacted]	‡	[redacted]	[redacted]	[redacted]		

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

DIUPRES-250

BP		MERCK	250MG;0.125MG	N11635 003 AUG 26, 1987		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		

DIUPRES-500

BP	+	MERCK	500MG;0.125MG	N11635 006 AUG 26, 1987		
[redacted]	‡	[redacted]	[redacted]	[redacted]		

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

	+	MERCK	EQ 500MG BASE/VIAL	N11145 005		
	‡	[redacted]	[redacted]	[redacted]		

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

[redacted]		[redacted]	[redacted]	[redacted]	>DLT>	[redacted]
	●		4MG	N80696 001	>ADD>	

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●	25MG/ML	N89563 001 APR 15, 1988	

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

[redacted]		[redacted]	[redacted]	[redacted]	>DLT>	[redacted]
	●		250MG	N86901 001	>ADD>	
[redacted]		[redacted]	[redacted]	[redacted]		
AA		WATSON LABS	500MG	N81040 001 AUG 22, 1989		

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74347 001 MAY 28, 1998	
AB		EQ 4GM RESIN/SCOOPFUL	N74347 002 MAY 28, 1998	

CHOLESTYRAMINE LIGHT

AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74555 001 SEP 30, 1998	>ADD>	
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74348 001 MAY 28, 1998	>ADD>	
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002 MAY 28, 1998		

LOCHOLEST

AB	ECR	EQ 4GM RESIN/PACKET	N74561 001 AUG 15, 1996	

CHOLESTYRAMINE

POWDER; ORAL

LOCHOLEST
AB ECR [redacted] EQ 4GM RESIN/SCOOPFUL N74561 002 AUG 15, 1996
[redacted] EQ 4GM RESIN/PACKET [redacted]
[redacted] EQ 4GM RESIN/SCOOPFUL [redacted]

LOCHOLEST LIGHT
AB ECR EQ 4GM RESIN/PACKET N74562 001 AUG 15, 1996
AB EQ 4GM RESIN/SCOOPFUL N74562 002 AUG 15, 1996
[redacted] EQ 4GM RESIN/PACKET [redacted]
[redacted] EQ 4GM RESIN/SCOOPFUL [redacted]

CIMETIDINE

SOLUTION; ORAL

CIMETIDINE HCL
AA DURAMED 300MG/5ML N75110 001 JUN 18, 1998

TABLET; ORAL

CIMETIDINE
AB [redacted] [redacted] [redacted]
AB [redacted] [redacted]
AB [redacted] [redacted]
AB [redacted] [redacted]
AB ZENITH LABS 200MG N74424 001 JUL 28, 1995
AB 300MG N74424 002 JUL 28, 1995
AB 400MG N74424 003 JUL 28, 1995
AB 800MG N74424 004 JUL 28, 1995

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HCL
AA COPLEY PHARM EQ 300MG BASE/5ML N74859 001 JUL 09, 1998

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN
+ ALCON EQ 0.3% BASE N20369 001 MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC
+ BAYER EQ 0.2% BASE;1% N20805 001 FEB 10, 1998

CISAPRIDE MONOHYDRATE

TABLET; ORAL

PROPULSID QUICKSOLV
[redacted] JANSSEN [redacted] [redacted] [redacted]

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV
+ JANSSEN EQ 20MG BASE N20767 001 NOV 07, 1997

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CELEXA
FOREST LABS EQ 20MG BASE N20822 002 JUL 17, 1998
EQ 40MG BASE N20822 003 JUL 17, 1998
+ EQ 60MG BASE N20822 004 JUL 17, 1998

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA	MORTON GROVE	EQ 0.5MG BASE/5ML	N74863 001	MAR 13, 1998

CLIDINIUM BROMIDE

[redacted]

>DLT>				
>DLT>				
>DLT>				
>DLT>				
>ADD>	●	2.5MG	N10355 001	
>ADD>	●	5MG	N10355 002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

>DLT>	[redacted]	[redacted]	[redacted]	
>DLT>				
>ADD>	●	EQ 75MG BASE	N63082 001	JUL 31, 1991
>ADD>				

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN 3

+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002	MAR 02, 1998

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

[redacted]				
	●	EQ 150MG BASE/ML	N62913 001	OCT 20, 1988

SOLUTION; TOPICAL

CLEOCIN T

[redacted]				
	●	EQ 1% BASE	N62363 001	FEB 08, 1982

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	STIEFEL	0.05%	N75057 001	AUG 12, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

>ADD>	AB	CHELSEA LABS	25MG	N74751 001	SEP 30, 1998
>ADD>					
>ADD>	AB		50MG	N74751 002	SEP 30, 1998
>ADD>					
>ADD>	AB		75MG	N74751 003	SEP 30, 1998
>ADD>					
	AB	MYLAN	25MG	N74947 001	APR 30, 1998
	AB		50MG	N74947 002	APR 30, 1998
	AB		75MG	N74947 003	APR 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	NOVOPHARM	0.5MG	N74920 001	AUG 04, 1998
AB		1MG	N74920 002	AUG 04, 1998
AB		2MG	N74920 003	AUG 04, 1998
[redacted]				

[redacted]

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

+	ROCHE	0.125MG	N20813 001	DEC 23, 1997
		0.25MG	N20813 002	DEC 23, 1997
		0.5MG	N20813 003	DEC 23, 1997
		1MG	N20813 004	DEC 23, 1997
+		2MG	N20813 005	DEC 23, 1997

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON

#	[redacted]	[redacted]	[redacted]	[redacted]
+	ROXANE	0.1MG/ML	N20615 001	OCT 02, 1996

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

>DLT>		ACTIFED W/ CODEINE			
>DLT>	AA	# [redacted]	[redacted]	[redacted]	[redacted]
>DLT>					
>DLT>					
>ADD>		●	10MG/5ML;30MG/5ML; 1.25MG/5ML	N12575 003	APR 04, 1984
>ADD>					
>ADD>		TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE			
>DLT>	AA	[redacted]	[redacted]	[redacted]	[redacted]
>DLT>					
>DLT>					
>ADD>	AA	+	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001	NOV 16, 1984
>ADD>					
>ADD>					

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLY-MYCIN M

#	[redacted]	[redacted]	[redacted]	[redacted]
+	PARKEDALE	EQ 150MG BASE/VIAL	N50108 002	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC
COLY-MYCIN S

#	[redacted]	[redacted]	[redacted]	[redacted]
+	PARKEDALE	EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML	N50356 001	

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH

#	[redacted]	[redacted]	[redacted]	[redacted]
#		[redacted]	[redacted]	[redacted]
●	PARKEDALE	25 UNITS/VIAL	N08317 002	
●		40 UNITS/VIAL	N08317 004	

CROMOLYN SODIUM

[redacted]
INTAL

#	[redacted]	[redacted]	[redacted]	[redacted]
●		20MG	N16990 001	

SOLUTION/DROPS; OPHTHALMIC
CROLOM

AT	BAUSCH AND LOMB	4%	N74443 001	JAN 30, 1995
#		4%	[redacted]	[redacted]

CROMOLYN SODIUM

AT	ADV REMEDIES	4%	N74706 001	APR 29, 1998

OPTICROM

AT	+ ALLERGAN	4%	N18155 001	OCT 03, 1984

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
OPTICROM
[redacted] [redacted] [redacted] [redacted]

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL
[redacted] [redacted] [redacted] [redacted]
AB WATSON LABS 10MG N74436 001 NOV 30, 1994

CYCLOSPORINE

CAPSULE; ORAL
NEORAL
BX NOVARTIS 25MG N50715 001 JUL 14, 1995
BX 50MG N50715 003 JUL 14, 1995
BX + 100MG N50715 002 JUL 14, 1995
SANDIMMUNE
BX NOVARTIS 25MG N50625 001 MAR 02, 1990
BX 50MG N50625 003 NOV 23, 1992
BX + 100MG N50625 002
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]

[redacted] [redacted] [redacted] [redacted]
NEORAL
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]

CYCLOSPORINE

[redacted] [redacted] [redacted] [redacted]
NEORAL
[redacted] [redacted] [redacted] [redacted]

SOLUTION; ORAL
NEORAL
BX + NOVARTIS 100MG/ML N50716 001 JUL 14, 1995
SANDIMMUNE
BX + NOVARTIS 100MG/ML N50574 001 NOV 14, 1983
[redacted] [redacted] [redacted] [redacted]

[redacted] [redacted] [redacted] [redacted]
NEORAL
[redacted] [redacted] [redacted] [redacted]

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL
[redacted] [redacted] [redacted] [redacted]
> DLT > [redacted] 4MG [redacted]
> ADD > [redacted] 4MG N86580 001

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE
AP GENSIA SICOR PHARMS 200MG/VIAL N75259 002 AUG 27, 1998
DTIC-DOME
AP + BAYER 200MG/VIAL N17575 002

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN
+ MERCK 0.5MG/VIAL N50602 001
[redacted] [redacted] [redacted] [redacted]

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
* [redacted] [redacted] [redacted] N20287 004 JAN 30, 1998
\+ 10,000 IU/ML N20287 004 JAN 30, 1998

DANAZOL

CAPSULE; ORAL
DANAZOL
AB BARR 50MG N74582 003 MAY 29, 1998
AB 100MG N74582 002 MAY 29, 1998

DANOCRINE
AB SANOFI 50MG N17557 003
AB 100MG N17557 004

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE
\+ BEDFORD EQ 20MG BASE/VIAL N64103 001 FEB 03, 1995

DAUNORUBICIN HCL
* [redacted] [redacted] [redacted] N64103 001 FEB 03, 1995

DAUNORUBICIN HCL PRESERVATIVE FREE
AP \+ BEDFORD EQ 20MG BASE/VIAL N50731 001 JAN 30, 1998
AP GENSIA SICOR PHARMS EQ 20MG BASE/VIAL N64212 001 JUN 23, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE
\+ ORGANON 0.15MG;0.02MG N20713 001 APR 22, 1998

DESOXIMETASONE

GEL; TOPICAL
DESOXIMETASONE
AB TARO 0.05% N74904 001 JUL 14, 1998

TOPICORT
AB \+ HOECHST MARION RSSL 0.05% N18586 001 MAR 29, 1982

OINTMENT; TOPICAL
DESOXIMETASONE
AB ALTANA 0.25% N73440 001 APR 01, 1998

DEXAMETHASONE SODIUM PHOSPHATE

[redacted] [redacted] [redacted] [redacted]
DECADRON
* MERCK EQ 0.1MG PHOSPHATE/INH N13413 001
● EQ 0.1MG PHOSPHATE/INH N13413 001

[redacted] [redacted] [redacted]
DECADRON
* MERCK EQ 0.1MG PHOSPHATE/INH N14242 001
● EQ 0.1MG PHOSPHATE/INH N14242 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXEDRINE
AA * [redacted] [redacted] 5MG [redacted]
AA 5MG N84935 001

DEXTROSTAT
AA SHIRE RICHWOOD 5MG [redacted]
AA \+ 5MG N84051 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER
AP B BRAUN 10GM/100ML N18046 001
AP [redacted] [redacted] [redacted]
DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML N16730 001
AP 5GM/ML N16730 002

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 5% IN PLASTIC CONTAINER
[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19873 001 JUN 10, 1993
[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N19844 001 JUN 10, 1993
[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N19843 001 AUG 09, 1993
AP [redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N18274 001
AP [redacted]

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;75MG/100ML N18744 001 NOV 09, 1982
AP [redacted]

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML N19870 001 JUN 10, 1993
[redacted]

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 10GM/100ML;900MG/100ML N18047 001
[redacted]
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 5GM/100ML;900MG/100ML N18026 001
[redacted]

DIAZEPAM

>DLT>	[redacted]			
>DLT>	[redacted]			
>DLT>	‡ [redacted]	[redacted]	[redacted]	[redacted]
>ADD>	●	15MG	N18179 001	

INJECTABLE; INJECTION

	DIAZEPAM			
AB	[redacted]	[redacted]	[redacted]	[redacted]
	●	5MG/ML	N72371 001 JAN 29, 1993	

DICLOFENAC POTASSIUM

TABLET; ORAL

	CATAFLAM			
AB	+ CIBA	50MG	N20142 002 NOV 24, 1993	
	DICLOFENAC POTASSIUM			
AB	TEVA	50MG	N75219 001 AUG 06, 1998	

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	DICLOFENAC SODIUM			
AB	ALCON	0.1% †	N20809 001 MAY 04, 1998	
	VOLTAREN			
AB	+ CIBA	0.1%	N20037 001 MAR 28, 1991	

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

	DICYCLOMINE HCL			
AB	[redacted]	[redacted]	[redacted]	[redacted]
	●	20MG	N84600 001 JUL 29, 1985	

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE			
AB	ALTANA	0.05%	N75187 001 MAR 30, 1998	
	PSORCON			
AB	+ DERMIK LABS	0.05%	N20205 001 NOV 20, 1992	
AB	‡	0.05%	N20205 001 NOV 20, 1992	

DIGOXIN

INJECTABLE; INJECTION

	DIGOXIN			
AP	ABBOTT	0.25MG/ML	N40206 001 AUG 28, 1998	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARTIA XT			
	● ANDRX PHARMS	120MG	N74752 002 JUL 09, 1998	
	●	180MG	N74752 001 JUL 09, 1998	
	●	240MG	N74752 003 JUL 09, 1998	
	●	300MG	N74752 004 JUL 09, 1998	
	DILTIAZEM HCL			
AB2	MYLAN	120MG	N75124 002 MAR 18, 1998	
AB2		180MG	N75124 003 MAR 18, 1998	
AB2		240MG	N75124 001 MAR 18, 1998	
	DILTIAZEM XR			
AB2	TORPHARM	240MG	N74943 001 AUG 06, 1998	
	TIAZAC			
BC	BIOVAIL	120MG	[redacted]	
BC	+	120MG	N20401 001 SEP 11, 1995	

† SEE SECTION 1.4 OF INTRODUCTION

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
TIAZAC

[redacted]		[redacted]	[redacted]	
BC	◆	180MG	N20401 002 SEP 11, 1995	
[redacted]		[redacted]	[redacted]	
BC	◆	240MG	N20401 003 SEP 11, 1995	
[redacted]		[redacted]	[redacted]	
BC	◆	300MG	N20401 004 SEP 11, 1995	
		[redacted]	[redacted]	
	◆	360MG	N20401 005 SEP 11, 1995	

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998
AP	TAYLOR PHARMA	5MG/ML	N75086 001 APR 09, 1998

TABLET; ORAL
DILTIAZEM HCL

> DLT >	[redacted]	[redacted]	[redacted]	
> DLT >				
> DLT >	[redacted]	[redacted]	[redacted]	
> DLT >				
> ADD >	●	30MG	N74084 001 FEB 25, 1994	
> ADD >				
> ADD >	●	60MG	N74084 002 FEB 25, 1994	
> ADD >				

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

	◆	HOECHST MARION RSSL	EQ 120MG HCL	N20506 001 OCT 04, 1996
> DLT >	◆		EQ 180MG HCL	N20506 002 OCT 04, 1996
> DLT >				
> ADD >				
> ADD >				

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

	◆	HOECHST MARION RSSL	EQ 240MG HCL	N20506 003 [redacted]
	◆	[redacted]	[redacted]	
	◆		[redacted]	
	◆		[redacted]	

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

[redacted]	[redacted]	[redacted]	[redacted]
	◆ FOREST LABS	10MG	N20411 001 MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

[redacted]	[redacted]	[redacted]	[redacted]
	●	12.5MG/5ML	N83237 001 JAN 25, 1982

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

> ADD > AP	AM PHARM PARTNERS	5MG/ML	N74956 001 SEP 30, 1998
> ADD > AP	BEDFORD	5MG/ML	N74939 001 APR 13, 1998

TABLET; ORAL
DIPYRIDAMOLE

[redacted]	[redacted]	[redacted]	[redacted]	
> DLT >	●	25MG	N89425 001 JUL 12, 1990	
> DLT >				
> ADD >				
> ADD >				

DISOPYRAMIDE PHOSPHATE

[illegible]

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001	JUN 25, 1998
AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001	FEB 18, 1998
AP		EQ 12.5MG BASE/ML	N74995 001	MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

> ADD >	+ MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001	APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

AB	[illegible]	[illegible]	[illegible]	[illegible]
AB		[illegible]	[illegible]	[illegible]
AB		[illegible]	[illegible]	[illegible]
AB	WATSON LABS	EQ 10MG BASE	[illegible]	MAR 29, 1991
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

RUBEX

AP	[illegible]	[illegible]	[illegible]	[illegible]
AP		[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	[illegible]	APR 13, 1989
AP		50MG/VIAL	N62926 002	APR 13, 1989
		100MG/VIAL	N62926 003	APR 13, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

PERIOSTAT

> ADD >	+ COLLAGENEX	EQ 20MG BASE	N50744 001	SEP 30, 1998

LIQUID, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

> ADD >	+ ATRIX	EQ 10% W/W	N50751 001	SEP 03, 1998

DROPERIDOL

INJECTABLE; INJECTION

INAPSINE

AP	+ AKORN MFG	2.5MG/ML	N16796 001	[illegible]
AP	+ [illegible]	[illegible]	[illegible]	[illegible]

DYPHYLLINE

[illegible]

	# [illegible]	[illegible]	[illegible]	[illegible]
	@	250MG/ML	N09088 001	

ECHOTHIOPHATE IODIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

>ADD<	+	AYERST	0.03%	N11963 002
>ADD<	+		0.06%	N11963 004
>ADD<	+		0.125%	N11963 001
>ADD<	+		0.25%	N11963 003
>DLT<	[redacted]	[redacted]	[redacted]	[redacted]
>DLT<	[redacted]	[redacted]	[redacted]	[redacted]
>DLT<	[redacted]	[redacted]	[redacted]	[redacted]
>DLT<	[redacted]	[redacted]	[redacted]	[redacted]

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP	ABBOTT	10MG/ML	N40131 001	FEB 24, 1998

>ADD< **EFAVIRENZ**

CAPSULE; ORAL
SUSTIVA

>ADD<		DUPONT PHARMS	50MG	N20972 001 SEP 17, 1998
>ADD<			100MG	N20972 002 SEP 17, 1998
>ADD<	+		200MG	N20972 003 SEP 17, 1998

ENCAINIDE HYDROCHLORIDE

[redacted]

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
	●		25MG	N18981 002 DEC 24, 1986
	●		35MG	N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

	+	RHONE POULENC RORER	40MG/0.4ML	N20164 002 JAN 30, 1998
	+		60MG/0.6ML	N20164 003 MAR 27, 1998
	+		80MG/0.8ML	N20164 004 MAR 27, 1998
	+		100MG/ML	N20164 005 MAR 27, 1998

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN

	+	COR	75MG/100ML	N20718 002 MAY 18, 1998
	+		2MG/ML	N20718 001 MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

[redacted]		[redacted]	[redacted]	[redacted]
AT		AKORN	0.5%	N64030 001 JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN

[redacted]		[redacted]	[redacted]	[redacted]
	+	HEALTHPOINT	2%	N50584 001 JAN 10, 1985

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

[redacted]		[redacted]	[redacted]	[redacted]
AB			333MG	N60272 002

ERY-TAB

[redacted]		[redacted]	[redacted]	[redacted]
AB	+		250MG	N62298 001
[redacted]		[redacted]	[redacted]	[redacted]

ERYTHROMYCIN

TABLET, DELAYED RELEASE; ORAL
ERY-TAB
AB ◆ ABBOTT 333MG N62298 003 MAR 29, 1982
[redacted]
AB ◆ [redacted] N62298 002

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE
[redacted]

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC
◆ BAXTER PHARM PROD 10MG/ML N19386 001 AUG 15, 1988
● 100MG/ML N19386 003 DEC 31, 1986
◆ 250MG/ML N19386 002
[redacted]

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM
[redacted]
AB WATSON LABS 1MG N74818 001 AUG 19, 1997
AB 2MG N74818 002 AUG 19, 1997

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
ALORA
BX PROCTER AND GAMBLE 0.05MG/24HR N20655 001 DEC 20, 1996
BX 0.075MG/24HR N20655 002 DEC 20, 1996
BX 0.1MG/24HR N20655 003
[redacted]
CLIMARA
BX ◆ BERLEX 0.075MG/24HR N20375 003 MAR 23, 1998
ESCLIM
BX FOURNIER 0.025MG/24HR N20847 001 AUG 04, 1998
BX 0.0375MG/24HR N20847 002 AUG 04, 1998
BX 0.05MG/24HR N20847 003 AUG 04, 1998
BX 0.075MG/24HR N20847 004 AUG 04, 1998
BX 0.1MG/24HR N20847 005 AUG 04, 1998
FEMPATCH
BX ◆ PARKE DAVIS 0.025MG/24HR N20417 001 DEC 03, 1996

TABLET; ORAL
ESTRADIOL
AB ENDEAVOR 0.5MG N40138 001 JAN 30, 1998
AB 1MG N40138 002 JAN 30, 1998
AB 2MG N40138 003 JAN 30, 1998

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH
RHONE POULENC RORER 0.05MG/24HR;0.14MG/24HR N20870 001 AUG 07, 1998

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH
◆ RHONE POULENC RORER 0.05MG/24HR;0.25MG/24HR N20870 002 > ADD >
AUG 07, 1998 > ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL
[redacted] [redacted] [redacted]
● 1MG/ML N85470 001
● 3MG/ML N85470 002

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN
AO ◆ BRISTOL MYERS SQUIBB 20MG/ML N09402 004
AO ◆ 40MG/ML N09402 003
◆ 10MG/ML N09402 002
[redacted] [redacted] [redacted]

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELADUMONE
● BRISTOL MYERS SQUIBB 4MG/ML;90MG/ML N09545 001
[redacted] [redacted] [redacted]
DELADUMONE CB
● BRISTOL MYERS SQUIBB 8MG/ML;180MG/ML N09545 002
[redacted] [redacted] [redacted]

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPRO 14/14
◆ WYETH AYERST 0.625MG,0.625MG;5MG,5MG N20527 003
JAN 09, 1998 > ADD >
> ADD >
> ADD >

ESTROGENS, ESTERIFIED

TABLET; ORAL
MENEST
BS MONARCH PHARMS 0.3MG N84951 001
BS 0.625MG N84948 001
BS 2.5MG N84949 001
1.25MG N84950 001
[redacted] [redacted] [redacted]

ESTRONE

INJECTABLE; INJECTION
THELIN
[redacted] [redacted] [redacted]
● PARKEDALE 1MG/ML N03977 001
● 2MG/ML N03977 002
● 5MG/ML N03977 003

ETHACRYNATE SODIUM

INJECTABLE; INJECTION
EDECRIN
◆ MERCK EQ 50MG BASE/VIAL N16093 001
[redacted] [redacted] [redacted]

ETHACRYNIC ACID

TABLET; ORAL
EDECRIN
MERCK 25MG N16092 001
◆ 50MG N16092 002
[redacted] [redacted] [redacted]

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
PREVEN EMERGENCY CONTRACEPTIVE KIT
◆ GYNETICS 0.05MG;0.25MG N20946 001
SEP 01, 1998

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

>ADD	RX	+	WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997
>ADD			[redacted]	[redacted]	[redacted]	[redacted]
>DLT						
>DLT						

LEVLITE

>ADD	RX		BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998
>ADD			[redacted]	[redacted]	[redacted]	[redacted]
>DLT						
>DLT						

LEVORA 0.15/30-21

[redacted]			[redacted]	[redacted]	[redacted]	[redacted]
AB			WATSON LABS	0.03MG;0.15MG	M73592 001	DEC 13, 1993

TABLET; ORAL-28

ALESSE

>ADD	RX		WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997
>ADD			[redacted]	[redacted]	[redacted]	[redacted]
>DLT						
>DLT						

LEVLITE

>ADD	RX		BERLEX LABS	0.02MG;0.1MG	N20860 002	JUL 13, 1998
>ADD			[redacted]	[redacted]	[redacted]	[redacted]
>DLT						
>DLT						

LEVORA 0.15/30-28

[redacted]			[redacted]	[redacted]	[redacted]	[redacted]
AB			WATSON LABS	0.03MG;0.15MG	M73594 001	DEC 13, 1993

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

[redacted]			[redacted]	[redacted]	[redacted]	[redacted]
AB			WATSON LABS	0.035MG;1MG	M71480 001	APR 12, 1988

TABLET; ORAL-28

NORETHIN 1/35E-28

[redacted]			[redacted]	[redacted]	[redacted]	[redacted]

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHIN 1/35E-28

AB			WATSON LABS	0.035MG;1MG	M71481 001	APR 12, 1988

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB			ABSGEN	300MG	M74929 001	JAN 30, 1998
AB			GENPHARM	200MG	M75071 001	SEP 30, 1998
AB				300MG	M75071 002	SEP 30, 1998
AB			TARO	200MG	M75078 001	APR 30, 1998
AB				300MG	M75078 002	APR 30, 1998

TABLET; ORAL

ETODOLAC

AB			CHELSEA LABS	400MG	M75069 001	APR 16, 1998
AB			GENPHARM	400MG	M75012 001	SEP 30, 1998
AB				500MG	M75012 002	SEP 30, 1998
AB			MYLAN	400MG	M75104 001	FEB 06, 1998
[redacted]			[redacted]	[redacted]	[redacted]	[redacted]
AB			TARO	400MG	M75074 001	MAR 11, 1998
AB			WATSON LABS	400MG	M74892 001	APR 16, 1997

LODINE

>ADD	AB	+	WYETH AYERST	500MG	N18922 005	JUN 28, 1996
>ADD						

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

		+	WYETH AYERST	500MG	N20584 003	JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

> ADD >	AP	APPLIED ANAL	20MG/ML	N74983 001	
> ADD >				SEP 30, 1998	
	AP	MARSAM	20MG/ML	N74968 001	
				JAN 09, 1998	

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

> DLT >	#	[redacted]	EQ [redacted] BASE/VIAL	[redacted]	
> DLT >				[redacted]	
> DLT >		ETOPOPHOS PRESERVATIVE FREE			
> DLT >	◆	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001	
> ADD >				MAY 17, 1996	
> ADD >	◆		EQ 500MG BASE/VIAL	N20906 001	
> ADD >				FEB 27, 1998	

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

MERCK	20MG	N20752 001	
		MAY 28, 1998	
◆	40MG	N20752 002	
		MAY 28, 1998	

FENFLURAMINE HYDROCHLORIDE

[redacted]
[redacted]

#	[redacted]	[redacted]	[redacted]
●		20MG	N16618 001

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL

●	ABBOTT	100MG	N19304 001
			DEC 31, 1993
#	[redacted]	[redacted]	[redacted]
			[redacted]

FENOFIBRATE

CAPSULE; ORAL
TRICOR (MICRONIZED)

◆	ABBOTT	67MG	N19304 002
			FEB 09, 1998

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

AB	[redacted]	[redacted]	[redacted]
			[redacted]
AB	[redacted]	[redacted]	[redacted]
			[redacted]
	●	EQ 200MG BASE	N72981 001
			AUG 19, 1991
	●	EQ 300MG BASE	N72982 001
			AUG 19, 1991

FENTANYL CITRATE

INJECTABLE; INJECTION
[redacted]

AB	[redacted]	[redacted]	[redacted]
			[redacted]
AB	# [redacted]	[redacted]	[redacted]
			[redacted]

FENTANYL CITRATE PRESERVATIVE FREE

AP	ABBOTT	EQ 0.05MG BASE/ML	N72786 001
			SEP 24, 1991
AP	◆ ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001
			JUL 11, 1984
AP	MARSAM	EQ 0.05MG BASE/ML	N74917 001
			FEB 03, 1998

[redacted]

AB	# [redacted]	[redacted]	[redacted]

SUBLIMAZE PRESERVATIVE FREE

AP	◆ JANSSEN	EQ 0.05MG BASE/ML	N16619 001

FLOSEQUINAN

[redacted]
[redacted]

	[redacted]	[redacted]	[redacted]
			[redacted]

FLOSEQUINAN

TABLET; ORAL
MANOPLAX
KROLL PHARM 75MG N19960 002 DEC 30, 1992
* 100MG N19960 003 DEC 30, 1992
● 50MG N19960 001 DEC 30, 1992
● 75MG N19960 002 DEC 30, 1992
● 100MG N19960 003 DEC 30, 1992

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
AB DRAXIS HLTH 0.05% N72494 001 JAN 19, 1989
AB TARO 0.05% N72496 001 JAN 19, 1989

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
AP PHARMACIA AND UPJOHN 50MG/ML N81225 001 AUG 28, 1991
AP * 50MG/ML N81225 001 AUG 28, 1991

FLUOROURACIL
> ADD > AP AM PHARM PARTNERS 50MG/ML N40278 001 SEP 30, 1998
> ADD >
> ADD > AP 50MG/ML N40279 001 SEP 30, 1998
> ADD >

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE
AQ KING PHARMS 25MG/ML N74966 001 APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
CORDRAN-N
* LILLY 0.05%;EQ 3.5MG BASE/GM N50346 001
● 0.05%;EQ 3.5MG BASE/GM N50346 001

OINTMENT; TOPICAL
CORDRAN-N
* LILLY 0.05%;EQ 3.5MG BASE/GM N50345 001
● 0.05%;EQ 3.5MG BASE/GM N50345 001

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX
SOLVAY 25MG N20243 001 DEC 05, 1994
25MG N20243 001 DEC 05, 1994

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE
+ ISIS 6.6MG/ML N20961 001 AUG 26, 1998

GEMFIBROZIL

CAPSULE; ORAL
LOPID
PARKE DAVIS 200MG N18422 001
300MG N18422 002
● PARKE DAVIS PHARMS 200MG N18422 001
● 300MG N18422 002

TABLET; ORAL
GEMFIBROZIL
AB TORPHARM 600MG N75034 001 JUL 20, 1998

LOPID
AB # PARKE DAVIS 600MG N18422 003 NOV 20, 1986
AB + PARKE DAVIS PHARMS 600MG N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008 AUG 28, 1987		
AP		EQ 60MG BASE/100ML	N62814 009 AUG 28, 1987		
AP		EQ 70MG BASE/100ML	N62814 010 AUG 28, 1987		
AP		EQ 0.8MG BASE/ML	N62814 001 AUG 28, 1987		
AP		EQ 80MG BASE/100ML	N62814 011 AUG 28, 1987		
AP		EQ 90MG BASE/100ML	N62814 012 AUG 28, 1987		
AP		EQ 100MG BASE/100ML	N62814 013 AUG 28, 1987		
AP		EQ 1.2MG BASE/ML	N62814 002 AUG 28, 1987		
AP		EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987		
AP		EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987		
AP		EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987		
AP		EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987	> ADD >	
AP		EQ 2MG BASE/ML	N62814 006 AUG 28, 1987	> ADD >	
AP		EQ 2.4MG BASE/ML	N62814 007	> ADD >	
AP	MCGAW	[illegible]	[illegible]	> ADD >	
AP		[illegible]	[illegible]		
AP		[illegible]	[illegible]		
AP		[illegible]	[illegible]		
AP		[illegible]	[illegible]		
AP		[illegible]	[illegible]		
AP		[illegible]	[illegible]		
AP		[illegible]	[illegible]		
AP		[illegible]	[illegible]		

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	EQ 120MG BASE/100ML	[illegible]
AP		EQ 1.4MG BASE/ML	[illegible]
AP		EQ 1.6MG BASE/ML	[illegible]
AP		EQ 1.8MG BASE/ML	[illegible]
AP		EQ 2MG BASE/ML	[illegible]
AP		EQ 2.4MG BASE/ML	[illegible]

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001 JUN 22, 1998

GLUCAGON, BIOSYNTHETIC

INJECTABLE; INJECTION
GLUCAGON

+	LILLY	1MG/VIAL	N20928 001 SEP 11, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	INVAMED	1.5MG	N75174 001 JUN 22, 1998
AB		3MG	N75174 002 JUN 22, 1998
AB	MYLAN	1.5MG	N74792 001 JUN 26, 1998
AB		3MG	N74792 002 JUN 26, 1998

GLYCOPYRROLATE

TABLET; ORAL

>DLT>	AA	[redacted]	[redacted]	[redacted]	>ADD>		
>DLT>	AA	[redacted]	[redacted]	[redacted]	>ADD>		
>DLT>	AA	[redacted]	[redacted]	[redacted]	>ADD>		
>ADD>		●	1MG	N86902 001	>ADD>	AB	N86902 001
>ADD>		●	2MG	N86900 001	>ADD>	AB	N86900 001
		ROBINUL					
>DLT>	AA	# [redacted]	[redacted]	[redacted]			
>ADD>		+	1MG	N12827 001			
		ROBINUL FORTE					
>DLT>	AA	# [redacted]	[redacted]	[redacted]			
>ADD>		+	2MG	N12827 002			

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

		NEOSPORIN					
AT	#	[redacted]	[redacted]	[redacted]			
AT	+	MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001			

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

		KYTRIL					
	●	SMITHKLINE BEECHAM	EQ 2MG BASE	N20305 002 JUN 15, 1998			

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

		RAXAR					
	#	[redacted]	[redacted]	[redacted]	>DLT>	AB	[redacted]
					>DLT>		
			EQ 200MG BASE	N20695 001 NOV 06, 1997	>DLT>	AB	[redacted]
					>DLT>		
			EQ 400MG BASE	N20695 002 MAY 14, 1998	>ADD>		● 10MG N72113 001 AUG 27, 1991
					>ADD>		
					>ADD>		● 20MG N72353 001 AUG 27, 1991
	+		EQ 600MG BASE	N20695 003 MAY 14, 1998	>ADD>	AB	[redacted]
						AB	[redacted]

GUANABENZ ACETATE

TABLET; ORAL

		GUANABENZ ACETATE					
>ADD>	AB	ECN	EQ 4MG BASE	N74517 001 SEP 30, 1998			
>ADD>							
>ADD>	AB		EQ 8MG BASE	N74517 002 SEP 30, 1998			

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

[redacted]							
		[redacted]					
	#	[redacted]	[redacted]	[redacted]			
	●		10MG;25MG	N13553 001			

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

		GUANFACINE HCL					
AB		ROXCH LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997			
AB			EQ 2MG BASE	N74762 002 JUN 25, 1997			
AB		WATSON LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997			
AB			EQ 2MG BASE	N74762 002 JUN 25, 1997			

HALOPERIDOL

TABLET; ORAL

		HALOPERIDOL					
>DLT>	AB	[redacted]	[redacted]	[redacted]			
>DLT>							
>DLT>	AB		[redacted]	[redacted]			
>DLT>							
>ADD>		●	10MG	N72113 001 AUG 27, 1991			
>ADD>							
>ADD>		●	20MG	N72353 001 AUG 27, 1991			
>ADD>	AB	[redacted]	[redacted]	[redacted]			
	AB		[redacted]	[redacted]			

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	[redacted]	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]	[redacted]
	●	0.5MG	[redacted]	[redacted]
	●	1MG	NOV 03, 1986	N71072 001
	●	2MG	NOV 03, 1986	N71073 001
	●	5MG	NOV 03, 1986	N71074 001
	●	10MG	NOV 03, 1986	N71075 001
	●	20MG	AUG 04, 1987	N71076 001
			AUG 04, 1987	

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	BEDFORD	EQ 50MG BASE/ML	JAN 30, 1998	N74811 001
> ADD > AO		EQ 100MG BASE/ML	SEP 28, 1998	N75305 001

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	[redacted]	[redacted]	[redacted]	[redacted]
AP		[redacted]	[redacted]	[redacted]
	●	EQ 5MG BASE/ML	FEB 25, 1993	N72516 001
	●	EQ 5MG BASE/ML	FEB 25, 1993	N72517 001

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER

	● AM PHARM PARTNERS	10 UNITS/ML	DEC 05, 1985	N17029 017
	●	100 UNITS/ML	DEC 05, 1985	N17029 018
	● [redacted]	[redacted]	[redacted]	[redacted]
	●	[redacted]	[redacted]	[redacted]

HEPARIN LOCK FLUSH

AP	AM PHARM PARTNERS	10 UNITS/ML	MAY 06, 1982	N17029 007
AP		100 UNITS/ML		N17029 006
	●	100 UNITS/ML		N17651 010
AP	[redacted]	[redacted]	[redacted]	[redacted]
AP		[redacted]	[redacted]	[redacted]
	●	[redacted]	[redacted]	[redacted]

HEPARIN LOCK FLUSH PRESERVATIVE FREE

● AM PHARM PARTNERS	10 UNITS/ML	SEP 22, 1987	N17029 011
●	100 UNITS/ML	SEP 22, 1987	N17029 012
● [redacted]	[redacted]	[redacted]	[redacted]
●	[redacted]	[redacted]	[redacted]

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER

● AM PHARM PARTNERS	10 UNITS/ML	SEP 22, 1987	N17029 008
●	100 UNITS/ML	SEP 22, 1987	N17029 009
● [redacted]	[redacted]	[redacted]	[redacted]
●	[redacted]	[redacted]	[redacted]

HEPARIN SODIUM

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 001
AP		1,000 UNITS/ML	N17979 001
AP		5,000 UNITS/ML	N17651 006
AP		10,000 UNITS/ML	N17029 003
AP		10,000 UNITS/ML	N17979 002
AP		20,000 UNITS/ML	N17029 004
	●	1,000 UNITS/ML	N17651 005
	●	5,000 UNITS/ML	N17029 002
	●	5,000 UNITS/ML	N17979 003

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM
● AM PHARM PARTNERS 10,000 UNITS/ML N17651 003
● 20,000 UNITS/ML N17651 008
[redacted]
● 1,000 UNITS/ML N17651 001
● 5,000 UNITS/ML N17651 002
● 10,000 UNITS/ML N17651 003
● 20,000 UNITS/ML N17651 004

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN 200 UNITS/100ML N19953 001 JUL 20, 1992
● 200 UNITS/100ML N19042 001 MAR 29, 1985
[redacted]

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%
[redacted]
● 10,000 UNITS/100ML N18911 006 JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%
[redacted]
● 5,000 UNITS/100ML N18911 007 JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
[redacted]
5,000 UNITS/100ML N19339 001 MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
● B BRAUN 5,000 UNITS/100ML N19802 001 JUL 20, 1992
[redacted]

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 200 UNITS/100ML N19042 002 MAR 29, 1985
[redacted]

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 4,000 UNITS/100ML N19952 001 JUL 20, 1992
[redacted]

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
[redacted]
● 5,000 UNITS/100ML N18911 009 JAN 30, 1985
● 10,000 UNITS/100ML N18911 008 JAN 30, 1985

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5,000 UNITS/100ML N19952 004 JUL 20, 1992
AP 10,000 UNITS/100ML N19952 005 JUL 20, 1992
● 5,000 UNITS/100ML N19134 001 MAR 29, 1985
[redacted]

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
● B BRAUN 5,000 UNITS/100ML N19802 005 JUL 20, 1992
● 10,000 UNITS/100ML N19802 002 JUL 20, 1992
[redacted]

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985		
	●	5,000 UNITS/100ML	N19802 003 JUL 20, 1992	> DLT >	
	● MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985	> DLT >	
	●	5,000 UNITS/100ML	N19802 001 JUL 20, 1992	> ADD >	
	●	5,000 UNITS/100ML	N19802 002 JUL 20, 1992	> ADD >	

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985
	● MCGAW	1,000 UNITS/100ML	N19042 004 MAR 29, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP		20,000 UNITS/ML	N17029 016 DEC 05, 1985
AP	FUTURAMA	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP		20,000 UNITS/ML	N17029 016 DEC 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	+ AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986	
AP	+ FUTURAMA	1,000 UNITS/ML	N17029 010 APR 28, 1986	

HEPFLUSH-10

AP	AM PHARM PARTNERS	10 UNITS/ML	N17651 009 JUN 26, 1984
AP	FUTURAMA	10 UNITS/ML	N17651 009 JUN 26, 1984

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

AP	+ NOVARTIS	20MG/ML	N08303 003	
	●	20MG/ML	N08303 003	

HYDRALAZINE HCL

AP	ZUBRIGEN	20MG/ML	N40136 001 JUN 30, 1997	
AP	+	20MG/ML	N40136 001 JUN 30, 1997	
AP	SOLOHRAX	20MG/ML	N88517 001 AUG 22, 1985	
AP	+	20MG/ML	N88517 001 AUG 22, 1985	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVAPRO HCT

	● SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
	+	12.5MG;150MG	N20758 002 SEP 30, 1997

IRBESARTAN-HYDROCHLOROTHIAZIDE

	● SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
	+	12.5MG;150MG	N20758 002 SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	ZYDUS	15MG;250MG	N70829 001 MAR 09, 1987	
AB		25MG;250MG	N70830 001 MAR 09, 1987	
	●	15MG;250MG	N70829 001 MAR 09, 1987	
	●	25MG;250MG	N70830 001 MAR 09, 1987	

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

> DLT >	AB	[redacted]	[redacted]	[redacted]
> DLT >	AB	[redacted]	[redacted]	[redacted]
> DLT >	AB	[redacted]	[redacted]	[redacted]
> DLT >				
> ADD >	•		25MG;40MG	N71498 001 DEC 18, 1991
> ADD >				
> ADD >	•		25MG;80MG	N71501 001 DEC 18, 1991
> ADD >				

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROPRES 25

BP		MERCK	25MG;0.125MG	N11958 002
BP	‡	[redacted]	[redacted]	[redacted]

HYDROPRES 50

BP	+	MERCK	50MG;0.125MG	N11958 003
BP	‡	[redacted]	[redacted]	[redacted]

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB		GENEVA PHARMS	25MG;25MG	N86881 001

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

AB		[redacted]	[redacted]	[redacted]

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL
TIMOLIDE 10-25

	+	MERCK	25MG;10MG	N18061 001
	‡	[redacted]	[redacted]	[redacted]

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		BARR	25MG;37.5MG	N74970 001 JAN 06, 1998

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		BARR	25MG;37.5MG	N71251 002 MAY 05, 1998

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT

		NOVARTIS	12.5MG;80MG	N20818 001 MAR 06, 1998
	+		12.5MG;160MG	N20818 002 MAR 06, 1998

HYDROCORTISONE

CREAM; TOPICAL
ANUSOL HC

AT		[redacted]	2.5%	[redacted]
AT		PARKEDALE	2.5%	N88250 001 JUN 06, 1984

SOLUTION; TOPICAL
TEXACORT

AT	‡	[redacted]	1%	[redacted]
AT	+	MEDICIS	1%	N80423 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
CORTISPORIN

AT	‡	[redacted]	[redacted]	[redacted]
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001

SUSPENSION/DROPS; OTIC
CORTISPORIN

AT	‡	[redacted]	[redacted]	[redacted]
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB		COPLEY PHARM	0.2%	N74489 001 AUG 12, 1998
AB		TARO	0.2%	N75042 001 AUG 25, 1998

WESTCORT

AB	+	WESTWOOD SQUIBB	0.2%	N17950 001

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		TARO	0.2%	N75043 001 AUG 25, 1998

WESTCORT

AB	+	WESTWOOD SQUIBB	0.2%	N18726 001 AUG 08, 1983

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

DILAUDID

AA	+	KNOLL PHARM	5MG/5ML	N19891 001 DEC 07, 1992

HYDROMORPHONE HCL

AA		ROXANE	5MG/5ML	N74653 001 JUL 29, 1998

TABLET; ORAL

DILAUDID

AB	+	KNOLL PHARM	8MG	N19892 001 DEC 07, 1992

HYDROMORPHONE HCL

AB		ROXANE	8MG	N74597 001 JUL 29, 1998

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

	+	AKORN	1%;0.25%	N19261 001 JAN 30, 1992
		[redacted]	[redacted]	[redacted]

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		MYLAN	200MG	N40274 001 MAY 29, 1998

HYDROXYCHLOROQUINE SULFATE

		[redacted]	[redacted]	[redacted]
AB		WATSON LABS	200MG	N40133 001 NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL

DROXIA

		[redacted]	[redacted]	[redacted]
			200MG	N16295 002 FEB 25, 1998
			300MG	N16295 003 FEB 25, 1998
	+		400MG	N16295 004 FEB 25, 1998

HYDREA

AB	+	BRISTOL MYERS SQUIBB	500MG	N16295 001
		[redacted]	[redacted]	[redacted]

HYDROXYUREA

AB		DURAMED	500MG	N75020 001 JUL 30, 1998

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

		[redacted]	[redacted]	[redacted]
			[redacted]	[redacted]
			[redacted]	[redacted]
AB		WATSON LABS	10MG	[redacted] MAR 18, 1994
AB			25MG	N81150 001 MAR 18, 1994
AB			50MG	N81151 001 MAR 18, 1994

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

> DLT >	RX	[redacted]	[redacted]	[redacted]	
> DLT >					
> DLT >	RX		[redacted]	[redacted]	
> DLT >					
> ADD >		●	EQ 50MG HCL	N87767 001 AUG 16, 1982	
> ADD >					
> ADD >		●	EQ 100MG HCL	N87790 001 AUG 16, 1982	
> ADD >					

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL

	RX	[redacted]	[redacted]	[redacted]	
	BX	WHITEHALL ROBINS	100MG/5ML	N19833 002 SEP 19, 1989	

IBUPROFEN

	AB	ALPHARMA	100MG/5ML	N74978 001 MAR 25, 1998	

MOTRIN

	AB	+ MCNEIL	100MG/5ML	N19842 001 SEP 19, 1989	
	RX	#	[redacted]	[redacted]	

TABLET; ORAL

IBUPROFEN

	RX	[redacted]	[redacted]	[redacted]	
	RX		[redacted]	[redacted]	
	RX		[redacted]	[redacted]	
		●	400MG	N72064 001 JAN 14, 1988	> DLT >
		●	600MG	N72065 001 JAN 14, 1988	> DLT >
		●	800MG	N71938 001 JAN 14, 1988	> ADD >

IMDAPAMIDE

TABLET; ORAL

IMDAPAMIDE

AB	ALPHAPHARM	1.25MG	N75105 001 JUL 23, 1998	
AB		2.5MG	N75105 002 JUL 23, 1998	
AB	TEVA	1.25MG	N74498 002 FEB 12, 1998	

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

RX	[redacted]	[redacted]	[redacted]	> DLT >
RX		[redacted]	[redacted]	> DLT >
	●	25MG	N72996 001 JUL 31, 1991	> ADD >
	●	50MG	N72997 001 JUL 31, 1991	> ADD >
AB	ECN	75MG	N74464 001 MAY 28, 1998	> ADD >

INSULIN LISPRO

INJECTABLE; INJECTION

HUMALOG PEN

	+ LILLY	100 UNITS/ML	N20563 002 AUG 06, 1998	

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

	[redacted]	[redacted]	[redacted]	> DLT >
	# BRACCO	[redacted]	[redacted]	> DLT >
	●	24%	N17903 001	> ADD >

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

AP	ELKINS SINN	51%	N74629 004 MAR 31, 1998	

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250

AP	ABBOTT	51%	N75005 001	FEB 24, 1998

IOPAMIDOL-300

AP	ABBOTT	61%	N75005 002	FEB 24, 1998

IOPAMIDOL-370

AP	ABBOTT	76%	N75005 003	FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

[redacted]	[redacted]	[redacted]	[redacted]
	BERLEX LABS	40.6%	N19580 001 DEC 07, 1989

OSMOVIST 240

[redacted]	[redacted]	[redacted]	[redacted]
	BERLEX LABS	51.3%	N19580 002 DEC 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+	MALLINCKRODT	51%	N20923 001	MAY 28, 1998

OPTIRAY 320

+	MALLINCKRODT	68%	N20923 002	MAY 29, 1998

OPTIRAY 350

+	MALLINCKRODT	74%	N20923 003	MAY 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

+	BOEHRINGER INGELHEIM	0.018MG/INH	N19085 001	DEC 29, 1986

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISUPREL

> DLT >	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
> ADD >	+		0.103MG/INH		N11178 001

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
			[redacted]	[redacted]
			[redacted]	[redacted]
		@	2.5MG	N16191 002 APR 01, 1996
		@	5MG	N16191 001 APR 01, 1996

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

> ADD >	AB	+	SCHERING	60MG	N20225 002
> ADD >					AUG 12, 1993

ISOSORBIDE MONONITRATE

> ADD >	AB		ELAN PHARM	60MG	N75041 001
> ADD >					SEP 22, 1998

ISOSULFAN BLUE

INJECTABLE; INJECTION

LYMPHAZURIN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
+	US SURGCL	1%	N18310 001	

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

AP	+	PARKE DAVIS		[illegible]
AP	+	PARKEDALE		N16812 002
AP	+			N16812 003
	+			N16812 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

+	WYETH AYERST	100MG	N19816 001 FEB 08, 1995
+		150MG	N19816 002 FEB 08, 1995
		100MG	N19816 003 FEB 08, 1995
		150MG	N19816 002 FEB 08, 1995

LABETALOL HYDROCHLORIDE

TABLET; ORAL
LABETALOL HCL

AB		EON	100MG	N75113 001 AUG 04, 1998
AB			200MG	N75113 002 AUG 04, 1998
AB			300MG	N75113 003 AUG 04, 1998
>ADD< >ADD< >ADD< >ADD< >ADD<	AB	TEVA	100MG	N74989 001 SEP 30, 1998
	AB		200MG	N74989 002 SEP 30, 1998
	AB		300MG	N74989 003 SEP 30, 1998
>ADD< >ADD< >ADD<	AB	WATSON LABS	100MG	N75133 001 AUG 03, 1998
	AB		200MG	N75133 002 AUG 03, 1998
	AB		300MG	N75133 003 AUG 03, 1998

LABETALOL HYDROCHLORIDE

TABLET; ORAL
LABETALOL HCL

AB	ZENITH GOLDLINE	100MG	N74787 001 AUG 03, 1998
AB		200MG	N74787 002 AUG 03, 1998
AB		300MG	N74787 003 AUG 03, 1998

LACTULOSE

POWDER FOR RECONSTITUTION; ORAL
LACTULOSE

	INALCO	10GM/PACKET	N74712 001 DEC 10, 1997
+		10GM/PACKET	N74712 001 DEC 10, 1997

LAMOTRIGINE

TABLET, CHEWABLE; ORAL
LAMICTAL CD

	GLAXO WELLCOME	5MG	N20764 001 AUG 24, 1998
		25MG	N20764 002 AUG 24, 1998
+		100MG	N20764 003 AUG 24, 1998

LEFLUNOMIDE

TABLET; ORAL
ARAVA

	QUINTILES	10MG	N20905 001 SEP 10, 1998
		20MG	N20905 002 SEP 10, 1998
+		100MG	N20905 003 SEP 10, 1998

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN
+ HOECHST MARION RSSL 50MG/VIAL N20807 001
MAR 06, 1998

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LEUPROLIDE ACETATE
AP BEDFORD 1MG/0.2ML N74728 001
AUG 04, 1998

LUPRON
AP + TAP HOLDINGS 1MG/0.2ML N19010 001
APR 09, 1985

LEVODOPA

CAPSULE; ORAL
DOPAR
> DLT > [illegible]
> DLT > [illegible]
> DLT > [illegible]
> ADD > ● 100MG N16913 003
> ADD > + 250MG N16913 001
> ADD > ● 500MG N16913 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
LEVO-DROMORAN
+ ICN 2MG/ML N08719 001
DEC 19, 1991
[illegible]

TABLET; ORAL
LEVO-DROMORAN
+ ICN 2MG N08720 001
DEC 19, 1991
[illegible]

LIDOCAINE

DISC; ORAL
XYLOCAINE
[illegible] [illegible] [illegible]
+ ASTRA PHARMS 10% N14394 001

LIDOCAINE; PRILOCAINE

DISC; TOPICAL
EMLA
+ ASTRA PHARMS 2.5%;2.5% N20962 001
FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
[illegible]
> DLT > AP ABBOTT [illegible]
> DLT > AP [illegible]
> DLT > AP [illegible]
> DLT > [illegible]
> DLT > AP [illegible]
> DLT > AP [illegible]
> DLT > [illegible]
> DLT > [illegible]
> DLT > [illegible]
> DLT > [illegible]
> DLT > AP INTL MEDICATION [illegible]
> ADD > LIDOCAINE HCL PRESERVATIVE FREE
> ADD > AP ABBOTT 1% N80408 001
> ADD > AP 1.5% N80408 002
> ADD > AP 4% N88295 001
> ADD > MAY 17, 1984
> ADD > AP AM PHARM PARTNERS 1% N80404 002
> ADD > AP 2% N17584 001
> ADD > AP 2% N80404 003
> ADD > AP 4% N17584 002
> ADD > AP ELKINS SINN 1% N84625 001
> ADD > AP 2% N84625 002
> ADD > AP INTL MEDICATION 20% N17702 001
> ADD > LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER
> ADD > AP ABBOTT 1% N40302 001
> ADD > SEP 28, 1998
> ADD > AP 2% N40302 002
> ADD > SEP 28, 1998
> DLT > [illegible]
> DLT > AP ASTRA [illegible] N16801 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

> DLT >		[redacted]			
> DLT >	AP	[redacted]	[redacted]	[redacted]	
> DLT >	AP	[redacted]	[redacted]	[redacted]	
> DLT >	AP	[redacted]	[redacted]	[redacted]	
> DLT >		[redacted]			
> DLT >	AP	[redacted]	[redacted]	[redacted]	
> ADD >		XYLOCAINE 4% PRESERVATIVE FREE			
> ADD >	AP	+ ASTRA PHARMS	4%	N10417 001	
> ADD >		XYLOCAINE PRESERVATIVE FREE			
> ADD >	AP	ASTRA PHARMS	2%	N16801 001	
> ADD >	AP		4%	N16801 002	
> ADD >	AP	+	10%	N16801 003	
> ADD >	AP	+	20%	N16801 004	

LISINOPRIL

TABLET; ORAL

	ZESTRIL			
AB	+ [redacted]	2.5MG	[redacted]	
AB		2.5MG	N19777 005	APR 29, 1993
AB		10MG	[redacted]	
AB	+	10MG	N19777 002	MAY 19, 1988

LORATADINE

[redacted]

TABLET, ORALLY DISINTEGRATING; ORAL

	CLARITIN REDITABS		
+	SCHERING	10MG	N20704 001 DEC 23, 1996

LORAZEPAM

INJECTABLE; INJECTION

	LORAZEPAM			
AP	AKORN	2MG/ML	N74974 001	JUL 23, 1998
> ADD > AP	ELKINS SINN	2MG/ML	N74496 001	SEP 28, 1998
> ADD > AP		4MG/ML	N74496 002	SEP 28, 1998
> ADD > AP	TAYLOR	2MG/ML	N75025 001	JUL 23, 1998

TABLET; ORAL

	LORAZEPAM			
AB	[redacted]	[redacted]	[redacted]	
AB		[redacted]	[redacted]	
AB		[redacted]	[redacted]	
AB	WATSON LABS	0.5MG	N72934 001	OCT 31, 1991
AB		1MG	N72927 001	OCT 31, 1991
AB		2MG	N72928 001	OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

	ALREX			
+	PHARMOS	0.2%	N20803 001	MAR 09, 1998
	LOTEMAX			
+	PHARMOS	0.5%	N20583 001	MAR 09, 1998
+		0.5%	N20841 001	MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

	LOXITANE C			
AB	[redacted]	[redacted]	[redacted]	
+	WATSON LABS	EQ 25MG BASE/ML	N17658 001	

LOXAPINE HYDROCHLORIDE

INJECTABLE; INJECTION
LOXITANE IM
◈ COCENSYS EQ 50MG BASE/ML N18039 001
+ WATSON LABS EQ 50MG BASE/ML N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE
AB COCENSYS [illegible] N17525 001
AB [illegible] N17525 002
AB ◈ [illegible] N17525 003
AB [illegible] N17525 004
AB WATSON LABS [illegible] N17525 001
AB [illegible] N17525 002
AB ◈ [illegible] N17525 003
AB [illegible] N17525 004

TABLET; ORAL
LOXITANE
◉ COCENSYS EQ 10MG BASE N17525 006
◉ EQ 25MG BASE N17525 007
◉ EQ 50MG BASE N17525 008
◉ WATSON LABS EQ 10MG BASE N17525 006
◉ EQ 25MG BASE N17525 007
◉ EQ 50MG BASE N17525 008

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON
◈ BERTEK EQ 85MG BASE/GM N16763 001
◈ DOW HICKAM EQ 85MG BASE/GM N16763 001

POWDER FOR RECONSTITUTION; TOPICAL
SULFAMYLON
+ MYLAN 5% N19832 003
JUN 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19696 001 SEP 29, 1989
MCGAW 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19696 001 SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER
AP B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N18252 001
AP 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19711 001 SEP 29, 1989
AP MCGAW 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N18252 001
AP 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19711 001 SEP 29, 1989

MALATHION

LOTION; TOPICAL
OVIDE
◉ GENDERM 0.5% N18613 001 AUG 02, 1982
◉ MEDICIS 0.5% N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER
AP B BRAUN 10GM/100ML N20006 002 JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER

AP	MCGAW	10GM/100ML	N20006 002 JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP	B BRAUN	15GM/100ML	N20006 003 JUL 26, 1993
AP	MCGAW	15GM/100ML	N20006 003 JUL 26, 1993

MANNITOL 20%

AP	B BRAUN	20GM/100ML	N14738 001
AP	MCGAW	20GM/100ML	N14738 001

MANNITOL 20% IN PLASTIC CONTAINER

AP	B BRAUN	20GM/100ML	N20006 004 JUL 26, 1993	> DLT > > ADD >
AP	MCGAW	20GM/100ML	N20006 004 JUL 26, 1993	

MANNITOL 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML	N20006 001 JUL 26, 1993
AP	MCGAW	5GM/100ML	N20006 001 JUL 26, 1993

SOLUTION; IRRIGATION
RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N16772 002
	MCGAW	5GM/100ML	N16772 002

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE

+	LAYTON	2.5MG	N10251 001
+	MERCK SHARP DOHME	2.5MG	N10251 001

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	PHARMACHEMIE	40MG	N74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

AA	ROXCH LABS	50MG	N40186 001 JUN 30, 1997
AA	WATSON LABS	50MG	N40186 001 JUN 30, 1997

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA	DANBURY PHARMA	400MG	N84274 001
	@	600MG	N84274 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

+	HOECHST MARION ROSS	250MG	N20049 001 MAY 10, 1993
+	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21

AB	SEARLE	0.05MG;1MG	N71539 001 APR 12, 1988
AB	WATSON LABS	0.05MG;1MG	N71539 001 APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/50M-28

AB	SEARLE	0.05MG;1MG	N71540 001 APR 12, 1988
AB	WATSON LABS	0.05MG;1MG	N71540 001 APR 12, 1988

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL

AA	ROXANE	10MG/ML	N40180 001 APR 30, 1998

TABLET; ORAL
METHADONE HCL

AA	ECN	5MG	N40241 001 MAY 29, 1998
AA		10MG	N40241 002 MAY 29, 1998

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	ECN	40MG	N75082 001 MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION
[redacted]

AP	[redacted]	[redacted]	[redacted]
	●	100MG/ML	N89849 001 DEC 27, 1991

TABLET; ORAL
[redacted]

AA	[redacted]	[redacted]	[redacted]
	●	750MG	N85136 001
	METHOCARBAMOL		
AA	[redacted]	[redacted]	[redacted]
	●	500MG	N85137 001

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

AA	[redacted]	[redacted]	[redacted]
AA		[redacted]	[redacted]
	●	EQ 5MG BASE	N72436 001 JUN 22, 1989

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

	● INVAMED	EQ 10MG BASE	N70850 001 FEB 03, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP	ABBOTT	1MG/ML	N75160 001 JUL 06, 1998

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	DANBURY PHARMA	150MG	N74865 001 APR 13, 1998
AB		200MG	N74865 002 APR 13, 1998
AB		250MG	N74865 003 APR 13, 1998

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	SUPERGEN	5MG/VIAL	N64144 001 APR 30, 1998
AP		20MG/VIAL	N64144 002 APR 30, 1998

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAIR

	+ MERCK	EQ 10MG BASE	N20829 002 FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR

	+ MERCK	EQ 5MG BASE	N20830 001 FEB 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	KADIAN			
	✦ FAULDING	20MG	N20616 001	JUL 03, 1996
	✦	50MG	N20616 002	JUL 03, 1996
	✦	100MG	N20616 003	
	✳ [redacted]	[redacted]	[redacted]	
	✳	[redacted]	[redacted]	
	✳	[redacted]	[redacted]	

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE			
AB	AB GENERICS	15MG	N74862 001	JUL 07, 1998
AB		30MG	N74862 002	JUL 07, 1998
AB		60MG	N74862 003	JUL 07, 1998
AB		100MG	N74769 001	JUL 02, 1998
AB		200MG	N74769 002	JUL 02, 1998
	MS CONTIN			
AB	✦ PURDUE FREDERICK	15MG	N19516 003	SEP 12, 1989
AB	✦	30MG	N19516 001	MAY 29, 1987
AB	✦	60MG	N19516 002	APR 08, 1988
AB	✦	100MG	N19516 004	JAN 16, 1990
AB	✦	200MG	N19516 005	
[redacted]	✳	[redacted]	[redacted]	
[redacted]	✳	[redacted]	[redacted]	
[redacted]	✳	[redacted]	[redacted]	
[redacted]	✳	[redacted]	[redacted]	

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

	CELLCEPT			
	✦ ROCHE GLOBAL	500MG/VIAL	N50758 001	AUG 12, 1998

NADOLOL

TABLET; ORAL

	CORGARD			
AB	BRISTOL MYERS SQUIBB	20MG	N18063 005	OCT 28, 1986
AB		40MG	N18063 001	
AB		80MG	N18063 002	
AB		120MG	N18063 003	
AB	✦	160MG	N18063 004	
[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]	✳	[redacted]	[redacted]	

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALBUPHINE HCL			
AP	KING PHARMS	10MG/ML	N74471 001	MAR 19, 1998
AP		20MG/ML	N74471 002	MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE HCL			
AP	[redacted]	[redacted]	[redacted]	
	●	0.4MG/ML	N70172 001	SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	ROXCO LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997	
AB	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997	

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB	BARR	50MG	N74918 001 MAY 08, 1998	

REVIA

AB	+ DUPONT MERCK	50MG	N18932 001 NOV 20, 1984	

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+ SYNTEX	375MG	N20067 002 OCT 14, 1994	
AB	+	500MG	N20067 003 OCT 14, 1994	

NAPROXEN

AB	INVAMED	375MG	N75061 001 FEB 18, 1998	
AB		500MG	N75061 002 FEB 18, 1998	
AB	PUREPAC PHARM	375MG	N74936 001 FEB 24, 1998	
AB		500MG	N74936 002 FEB 24, 1998	>ADD>
AB	TEVA	375MG	N75227 001 JUN 30, 1998	>ADD>
AB		500MG	N75227 002 JUN 30, 1998	>ADD>

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	AL HIKMA	EQ 250MG BASE	N74480 002 FEB 18, 1998	

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

	GLAXO WELLCOME	EQ 1MG BASE	N20763 002 FEB 10, 1998	
	+	EQ 2.5MG BASE	N20763 001 FEB 10, 1998	

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

	[illegible]	EQ 150MG BASE	N60304 001	
	+	EQ 350MG BASE	N60304 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT

AT	GLAXO WELLCOME	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001	
AT	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001	

NEVIRAPINE

SUSPENSION; ORAL
VIRAMUNE

	+ BOEHRINGER INGELHEIM	50MG/5ML	N20933 001 SEP 11, 1998	

NIACIN

TABLET; ORAL
NIACIN

>DLT>	AA	[illegible]	500MG	N83303 001

NIACIN

TABLET; ORAL

NIACIN

>ADD>	@ DANBURY PHARMA	500MG	N83305 001	

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HCL

AB	GENPHARM	20MG	N74928 001	MAR 19, 1998
AB		30MG	N74928 002	MAR 19, 1998

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB1		0.1MG/HR	N89771 001	AUG 30, 1996
[redacted]		[redacted]	[redacted]	[redacted]
AB1		0.2MG/HR	N89772 001	AUG 30, 1996
[redacted]		[redacted]	[redacted]	[redacted]
AB1		0.4MG/HR	N89773 001	AUG 30, 1996
[redacted]		[redacted]	[redacted]	[redacted]
AB1		0.6MG/HR	N89774 001	AUG 30, 1996

NITRO-DUR

[redacted]	[redacted] KEY PHARMS	[redacted]	[redacted]	[redacted]
AB1	+	0.1MG/HR	N20145 001	APR 04, 1995
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB1	+	0.2MG/HR	N20145 002	APR 04, 1995
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

AB1	+ KEY PHARMS	0.4MG/HR	N20145 004	APR 04, 1995
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB1	+	0.6MG/HR	N20145 005	APR 04, 1995

NITROGLYCERIN

AB2	MYLAN	0.1MG/HR	N75033 001	FEB 06, 1998
[redacted]		[redacted]	[redacted]	[redacted]
AB2		0.2MG/HR	N74609 001	AUG 30, 1996
[redacted]		[redacted]	[redacted]	[redacted]
AB2		0.4MG/HR	N74607 001	AUG 30, 1996
[redacted]		[redacted]	[redacted]	[redacted]
AB2		0.6MG/HR	N74559 001	AUG 30, 1996

TRANSDERM-NITRO

AB2	+ NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB2	+	0.2MG/HR	N20144 002	FEB 27, 1996
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB2	+	0.4MG/HR	N20144 003	FEB 27, 1996
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB2	+	0.6MG/HR	N20144 004	FEB 27, 1996
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

NORETHINDRONE

TABLET; ORAL

NOR-QD

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

NORETHINDRONE

TABLET; ORAL
NOR-QD
+ WATSON LABS — 0.35MG — N17060 001

NORETHINDRONE ACETATE

TABLET; ORAL
AYGESTIN
AB — [illegible] — [illegible] — [illegible]
AB + — 5MG — N18405 001 APR 21, 1982
[illegible]
AB [illegible] — [illegible] — [illegible]
● — 5MG — N12184 002

NYSTATIN

SUSPENSION; ORAL
MYSTATIN
AA UDL — 100,000 UNITS/ML — N64142 001 JUN 25, 1998

OLANZAPINE

TABLET; ORAL
ZYPREXA
[illegible] — [illegible] — [illegible]
+ — 2.5MG — N20592 001 SEP 30, 1996
● — 15MG — N20592 005 SEP 09, 1997
● — 20MG — N20592 006 SEP 09, 1997

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA MERCK — 40MG — N19810 002 JAN 15, 1998

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
NORFLEX
AB + 3N — 100MG — N12157 001
ORPHENADRINE CITRATE
AB INVAMED — 100MG — N40284 001 JUN 19, 1998

OXAZEPAM

TABLET; ORAL
SERAX
[illegible] — [illegible] — [illegible]
● — 15MG — N71494 001 APR 21, 1987
SERAX
AB [illegible] — [illegible] — [illegible]
+ — 15MG — N15539 008

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN
AA + ALZA — 5MG/5ML — N18211 001
AA [illegible] — [illegible] — [illegible]

TABLET; ORAL
DITROPAN
AB + ALZA — 5MG — N17577 001
AB [illegible] — [illegible] — [illegible]

OXYTOCIN

INJECTABLE; INJECTION
PITOCIN
AP [illegible] — [illegible] — [illegible]
AP + PARKEDALE — 10 USP UNITS/ML — N18261 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
+ ABBOTT — 0.005MG/ML — N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

AA		KING PHARMS	EQ 250MG BASE	N62310 001	> DLT >
[redacted]		[redacted]	[redacted]	[redacted]	> DLT >
AA	+	PARKEDALE	EQ 250MG BASE	N60521 001	> DLT >
[redacted]		[redacted]	[redacted]	[redacted]	> ADD >
					> ADD >

PAROMOMYCIN SULFATE

AA		CARACO	EQ 250MG BASE	N64171 001 JUN 30, 1997
[redacted]			[redacted]	[redacted]

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

	+	ALZA	100MG	N20193 001 SEP 26, 1996
[redacted]		[redacted]	[redacted]	[redacted]

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB		BIOVAIL	400MG	N75028 001 JUL 20, 1998
> ADD > AB		WATSON LABS	400MG	N75107 001 SEP 04, 1998

> ADD >

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	ALLERGAN	5%	N19855 001 AUG 25, 1989

PERMETHRIN

AB		ALPHARMA	5%	N74806 001 JAN 23, 1998

PHENAZOPYRIDINE HYDROCHLORIDE, SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTRISIN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●		100MG;500MG	N13294 001 SEP 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●		50MG;500MG	N19358 001 AUG 31, 1990

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●		37.5MG	N88414 001 OCT 19, 1983

TABLET; ORAL

PHENTERMINE HCL

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●		30MG	N88605 001 SEP 28, 1987

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP		BEDFORD	5MG/VIAL	N40235 001 MAR 11, 1998

REGITINE

AP	+	NOVARTIS	5MG/VIAL	N08278 003

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
PROMPT PHENYTOIN SODIUM

> DLT >	RX	# [redacted]	[redacted]	[redacted]
> ADD >		●	100MG	N80905 001
> DLT >	RX	[redacted]	[redacted]	[redacted]
> ADD >		+	100MG	N80259 001

PINDOLOL

TABLET; ORAL
PINDOLOL

RX	[redacted]	[redacted]	[redacted] APR 28, 1993
RX		[redacted]	[redacted] APR 28, 1993
	●	5MG	N74125 001 APR 28, 1993
	●	10MG	N74125 002 APR 28, 1993
RX	[redacted]	[redacted]	[redacted] FEB 27, 1995
RX		[redacted]	[redacted] FEB 27, 1995
AB	WATSON LABS	5MG	N74437 001 FEB 27, 1995
AB		10MG	N74437 002 FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER

+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001 FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003 FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002 FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM

RX	[redacted]	[redacted]	[redacted] SEP 29, 1995
RX		[redacted]	[redacted] SEP 29, 1995
AB	WATSON LABS	10MG	N74460 001 SEP 29, 1995
AB		20MG	N74460 002 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
[redacted]

RX	[redacted]	[redacted]	[redacted] AUG 31, 1993
	●	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
[redacted]

RX	+ [redacted]	[redacted]	[redacted]
	●	EQ 500,000 U BASE/VIAL	N62036 001
	POLYMYXIN B SULFATE		
AP	+ BEDFORD	EQ 500,000 U BASE/VIAL	N60716 001
RX	[redacted]	[redacted]	[redacted]

POWDER; FOR RX COMPOUNDING
POLY-RX

RX	[redacted]	[redacted]	[redacted]
	+	100,000,000 UNITS/BOT	N61578 001
	[redacted]		
RX	[redacted]	[redacted]	[redacted] JUL 27, 1983
	●	100,000,000 UNITS/BOT	N62455 001 JUL 27, 1983

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
AT ALCON 10,000 UNITS/ML; 1MG BASE/ML N64211 001 APR 13, 1998

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
K-LEASE
> DLT > AB SAVAGE LABS 8MEQ N73398 001 JAN 28, 1992
> DLT > AB 10MEQ N72427 001 MAR 28, 1990
> DLT >
> ADD > ● 8MEQ N73398 001 JAN 28, 1992
> ADD >
> ADD > ● 10MEQ N72427 001 MAR 28, 1990
> ADD >

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
AP B BRAUN 2MEQ/ML N85870 001
AP MCGAW 2MEQ/ML N85870 001
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER
AP + ABBOTT 29.8MG/ML N20161 006 AUG 11, 1998
AP + BAXTER HLTHCARE 29.8MG/ML N19904 002 DEC 26, 1989
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER
AP + ABBOTT 2.24GM/100ML N20161 003 AUG 11, 1998
AP + BAXTER HLTHCARE 2.24GM/100ML N19904 003 DEC 26, 1989
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
AP + ABBOTT 2.98GM/100ML N20161 004 AUG 11, 1998
AP + BAXTER HLTHCARE 2.98GM/100ML N19904 004 DEC 26, 1989

TABLET, EXTENDED RELEASE; ORAL
TEN-K
RX NOVARTIS 10MEQ N19381 001 APR 16, 1986
● 10MEQ N19381 001 APR 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;900MG/100ML N18708 001 SEP 29, 1989
● 37MG/100ML;900MG/100ML N19708 001 SEP 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 75MG/100ML;900MG/100ML N18708 002 SEP 29, 1989
● 75MG/100ML;900MG/100ML N19708 002 SEP 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 110MG/100ML;900MG/100ML N18708 003 SEP 29, 1989
● 110MG/100ML;900MG/100ML N19708 003 SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 220MG/100ML;900MG/100ML N18708 005 SEP 29, 1989
● 220MG/100ML;900MG/100ML N19708 005 SEP 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN 300MG/100ML;900MG/100ML N18708 006 SEP 29, 1989
● 300MG/100ML;900MG/100ML N19708 006 SEP 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
● B BRAUN 75MG/100ML;900MG/100ML N18722 001 NOV 09, 1982
● MCGAW 75MG/100ML;900MG/100ML N18722 001 NOV 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
● B BRAUN 150MG/100ML;900MG/100ML N18722 002 NOV 09, 1982
● MCGAW 150MG/100ML;900MG/100ML N18722 002 NOV 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
● B BRAUN 220MG/100ML;900MG/100ML N18722 003 NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
[redacted] [redacted] [redacted] [redacted]

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
● B BRAUN 300MG/100ML;900MG/100ML N18722 004 NOV 09, 1982
[redacted] [redacted] [redacted] [redacted]

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
PHARMACIA AND UPJOHN 0.5MG N20667 006 FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL
PRE-PRED
[redacted] [redacted] [redacted] [redacted]

PREDNISOLONE
AA WE PHARMS 15MG/5ML N40192 001 MAY 28, 1998

PRELONE
AA + MURO 15MG/5ML N89081 001 FEB 04, 1986

TABLET; ORAL
PREDNISOLONE
[redacted] [redacted] [redacted] [redacted]
RX + 5MG N80354 001
[redacted] [redacted] [redacted] [redacted]
● 5MG N80339 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
[redacted]
[redacted] [redacted] [redacted] [redacted] [redacted]

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
[redacted]
● AKORN EQ 0.23% PHOSPHATE;10% N74511 001 JUL 30, 1996

PREDNISONE

TABLET; ORAL
PREDNISONE
[redacted] [redacted] [redacted] [redacted]
> DLT > [redacted] [redacted] [redacted]
> DLT > [redacted] [redacted] [redacted]
> DLT > [redacted] [redacted] [redacted]
> ADD > ● 5MG N80353 001
> ADD > ● 10MG N86062 001
> ADD > ● 20MG N86061 001

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE
+ ELAN PHARMA 250MG/5ML N10401 001
[redacted] [redacted] [redacted] [redacted]

TABLET; ORAL
MYSOLINE
AB + ELAN PHARMA 250MG N09170 002
+ 50MG N09170 003
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL
[redacted] [redacted] [redacted] [redacted]
● 500MG N89284 001 JUN 23, 1986
[redacted] [redacted] [redacted] [redacted]
● 250MG N88958 001 DEC 02, 1985

PROCAN SR
[redacted] [redacted] [redacted] [redacted]

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAN SR

[redacted]	[redacted]	250MG	[redacted]		
			APR 01, 1982		
[redacted]	[redacted]	1GM	[redacted]		
			JAN 16, 1985		
AB	PARKEDALE	500MG	N86065 001		
AB		750MG	N87510 001		
			APR 01, 1982		
AB		1GM	N88489 001		
			JAN 16, 1985		

PROCHLORPERAZINE EDISYLATE

				>ADD<	
				>ADD<	

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

[redacted]	[redacted]	[redacted]	[redacted]		
			JUNE 08, 1988	>DLT<	
	●	EQ 5MG BASE/ML	N89675 001	>ADD<	
			DEC 05, 1988		

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

				>DLT<	
AB	TRIGEN	EQ 5MG BASE	N40268 001	>ADD<	
			FEB 27, 1998		
AB		EQ 10MG BASE	N40268 002		
			FEB 27, 1998		
AB	ZENITH GOLDLINE	EQ 5MG BASE	N40162 001		
			JAN 20, 1998		
AB		EQ 10MG BASE	N40162 002		
			JAN 20, 1998		

PROGESTERONE

				>DLT<	
				>DLT<	
				>ADD<	
				>ADD<	

CAPSULE; ORAL
PROMETRIUM

◆	SCHERING PLOUGH	100MG	N19781 001		
			MAY 14, 1998		

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	WARSAW	25MG/ML	[redacted]		
			MAY 02, 1988		
AP		50MG/ML	[redacted]		
			MAY 02, 1988		
	●	25MG/ML	N89463 001		
			MAY 02, 1988		
	●	50MG/ML	N89477 001		
			MAY 02, 1988		

SYRUP; ORAL
PROMETHAZINE HCL

AA	HI TECH PHARMA	6.25MG	N40026 001		
			SEP 25, 1998		

TABLET; ORAL
PROMETHAZINE HCL

[redacted]	[redacted]	[redacted]	[redacted]		
			JUNE 08, 1988	>DLT<	
	●	12.5MG	N89675 001	>ADD<	
			DEC 05, 1988		

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

[redacted]	[redacted]	[redacted]	[redacted]		
	●	65MG	N80908 002		
[redacted]	[redacted]	[redacted]	[redacted]		
	●	65MG	N83278 001		

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

[redacted]	[redacted]	[redacted]	[redacted]		
			OCT 06, 1986		
	●	60MG	N71098 001		
			OCT 06, 1986		
[redacted]	[redacted]	[redacted]	[redacted]		
			JUL 05, 1988		
[redacted]	[redacted]	[redacted]	[redacted]		
			JUL 05, 1988		
[redacted]	[redacted]	[redacted]	[redacted]		
			JUL 05, 1988		

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	[illegible]	60MG	[illegible]		
AB		80MG	[illegible]		
AB		90MG	[illegible]		
	●	10MG	JUL 05, 1988		
	●	20MG	N71687 001 JUL 05, 1988	>_ADD_> >_ADD_>	
	●	40MG	N71688 001 JUL 05, 1988	>_ADD_> >_ADD_>	
	●	60MG	N72197 001 JUL 05, 1988		
	●	80MG	N71689 001 JUL 05, 1988		
	●	90MG	N72198 001 JUL 05, 1988	>_DLT_> >_DLT_> >_DLT_> >_ADD_>	

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

>_DLT_>	AB	[illegible]	100MG	[illegible]	
>_ADD_>	●		100MG	N85584 001	
	AB	[illegible]	200MG	[illegible]	
	●		200MG	N84003 001	

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB	+	ROBINS AH	300MG	N12796 002	
AB	+	[illegible]	300MG	[illegible]	

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC

	[illegible]		EQ 15MG BASE/ML	[illegible]	
	+		EQ 15MG BASE/ML	N19675 001 DEC 30, 1988	

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	MYLAN		EQ 150MG BASE		N74552 001 JUL 30, 1998
AB			EQ 300MG BASE		N74552 002 JUL 30, 1998
AB	RANBAXY		EQ 150MG BASE		N75000 001 JAN 30, 1998
AB			EQ 300MG BASE		N75000 002 JAN 30, 1998
AB	ZENITH GOLDLINE		EQ 150MG BASE		N75165 001 SEP 30, 1998
AB			EQ 300MG BASE		N75165 002 SEP 30, 1998

RAUWOLFIA SERPENTINA

TABLET; ORAL
[illegible]

	[illegible]	50MG	[illegible]	
	●	50MG	N80907 001	

RIFAMPIN

CAPSULE; ORAL
RIFADIN

AB	HOECHST MARION RSSL	150MG		N62303 001

RIFAMPIN

AB	BON	150MG		N64150 002 JAN 02, 1998

RIFAPENTINE

TABLET; ORAL
PRIFTIN

+	HOECHST MARION RSSL	150MG		N21024 001 JUN 22, 1998

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

+	PROCTER AND GAMBLE	30MG		N20835 001 MAR 27, 1998

RIZATRIPTAN BENZOATE

TABLET; ORAL
MAXALT
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]

TABLET, ORALLY DISINTEGRATING; ORAL
MAXALT
MERCK EQ 5MG BASE N20864 001 JUN 29, 1998
+ EQ 10MG BASE N20864 002 JUN 29, 1998
MAXALT-MLT
MERCK EQ 5MG BASE N20865 001 JUN 29, 1998
+ EQ 10MG BASE N20865 002 JUN 29, 1998

SACROSIDASE

SOLUTION; ORAL
SUCRAID
+ ORPHAN MEDCL 8,500 IU/ML N20772 001 APR 09, 1998

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
[redacted] [redacted] [redacted]
+ 200MG N20828 001 NOV 07, 1997

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL
AB ESI LEDERLE 5MG N74641 001 AUG 02, 1996
[redacted] [redacted] [redacted]

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL
AB STASON 5MG N74912 001 APR 30, 1998

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA
PFIZER 25MG N20895 001 MAR 27, 1998
50MG N20895 002 MAR 27, 1998
+ 100MG N20895 003 MAR 27, 1998

SIMVASTATIN

TABLET; ORAL
ZOCOR
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
+ 5MG N19766 001 DEC 23, 1991
40MG N19766 004 DEC 23, 1991
+ 80MG N19766 005 JUL 10, 1998

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN 450MG/100ML N19635 001 MAR 09, 1988
● 450MG/100ML N18184 001
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN 900MG/100ML N17464 001

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	900MG/100ML	N19635 002	MAR 09, 1988
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

	● B BRAUN	3GM/100ML	N19635 003	MAR 09, 1988
	[redacted]	[redacted]	[redacted]	[redacted]

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

	● B BRAUN	5GM/100ML	N19635 004	MAR 09, 1988
	[redacted]	[redacted]	[redacted]	[redacted]

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

	● B BRAUN	1.87GM/100ML	N18186 001	
	[redacted]	[redacted]	[redacted]	

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP	B BRAUN	1.87GM/100ML	N20004 001	APR 21, 1992
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

[redacted]	[redacted]	[redacted]	[redacted]	
AA	◆	453.6GM/BOT	N11287 001	

KIONEX

AA	PADDOCK	454GM/BOT	N40029 001	FEB 06, 1998

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION

GENOTROPIN

	◆ PHARMACIA AND UPJOHN	13.8MG/VIAL	N20280 007	OCT 23, 1996

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

	● [redacted]	[redacted]	[redacted]	[redacted]
		[redacted]	[redacted]	[redacted]
	[redacted]	[redacted]	[redacted]	[redacted]
		120MG	N19865 005	APR 20, 1994
	◆	160MG	N19865 002	OCT 30, 1992
		240MG	N19865 003	OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 30%

AP	◆ PHARMACIA AND UPJOHN	30%	N19942 001	DEC 30, 1993

LIPOSYN III 30%

AP	◆ ABBOTT	30%	N20181 001	JAN 13, 1998

NUTRILIPID 10%

AP	◆ B BRAUN	10%	N19531 001	MAY 28, 1993
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

NUTRILIPID 20%

AP	◆ B BRAUN	20%	N19531 002	MAY 28, 1993
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

SPARFLOXACIN

TABLET; ORAL

	ZAGAM			
+	MYLAN	200MG	N20677 001	DEC 19, 1996
[redacted]				

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

	STREPTOMYCIN SULFATE			
AP	+ PFIZER	EQ 1GM BASE/VIAL	N60076 001	
		[redacted]		
	+	EQ 1GM BASE/2.5ML	N60111 001	
AP	PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

	SUCOSTRIN			
[redacted]		[redacted]	[redacted]	
	●	20MG/ML	N08847 001	

SUCRALFATE

TABLET; ORAL

	SUCRALFATE			
AB	RATIOPHARM	1GM	N74415 001	JUN 08, 1998

SUFENTANIL CITRATE

INJECTABLE; INJECTION

	SUFENTA			
AP	+ AKORN	EQ 0.05MG BASE/ML	N19080 001	MAY 04, 1984
[redacted]		[redacted]	[redacted]	

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

[redacted]				
	●	10%	N80025 001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SEPTRA			
[redacted]		[redacted]	[redacted]	
AP	+ MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001	

SUSPENSION; ORAL

[redacted]		[redacted]	[redacted]	
	SEPTRA			
[redacted]		[redacted]	[redacted]	
AB	MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	TEVA	200MG/5ML;40MG/5ML	N18812 001	JAN 28, 1983
AB		200MG/5ML;40MG/5ML	N18812 002	JUN 10, 1983
AB		200MG/5ML;40MG/5ML	N70028 001	JUN 02, 1987

TABLET; ORAL

	SEPTRA			
[redacted]		[redacted]	[redacted]	
AB	MONARCH PHARMS	400MG;80MG	N17376 001	
	SEPTRA DS			
[redacted]		[redacted]	[redacted]	
AB	MONARCH PHARMS	800MG;160MG	N17376 002	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	TEVA	400MG;80MG	N18242 001	
AB		800MG;160MG	N18242 002	

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE

[redacted]	[redacted]	[redacted]	[redacted]
	●	500MG	N89339 001 OCT 26, 1987

SULFINPYRAZONE

TABLET; ORAL
SULFINPYRAZONE

> DLT >	[redacted]	[redacted]	[redacted]
> DLT >			
> ADD >	●	100MG	N87667 001 MAY 26, 1982
> ADD >			

SUTILAINS

> DLT > [redacted]
> DLT > TRACADE
> DLT > [redacted] [redacted] [redacted]
> ADD > ● 82,000 UNITS/GM N12828 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

	[redacted]	[redacted]	[redacted]
		[redacted]	[redacted]
		[redacted]	[redacted]
	※	[redacted]	[redacted]
		PARKE DAVIS PHARMS EQ 10MG BASE	[redacted] SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
	✦	EQ 40MG BASE	N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
PROGRAF

	※ [redacted]	[redacted]	[redacted]
	※	[redacted]	[redacted]
	✦ FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001 APR 08, 1994
	✦	EQ 5MG BASE	N50708 002 APR 08, 1994

INJECTABLE; INJECTION
PROGRAF

	※ [redacted]	[redacted]	[redacted]
	✦ FUJISAWA HLTHCARE	EQ 5MG BASE/ML	N50709 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS	DRAXIMAGE	N/A	N17881 001 DEC 30, 1987
BS	[redacted]	N/A	[redacted]

> ADD > **TECHNETIUM TC-99M APCITIDE**

INJECTABLE; INJECTION
ACUTECT

> ADD >	DIATIDE	N/A	N20887 001 SEP 14, 1998

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

	[redacted]	[redacted]	[redacted]
	DUPONT PHARMS	N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
[redacted]
[redacted] [redacted] N/A [redacted]
◆ N/A N17907 001
TECHNESCAN GLUCEPTATE
[redacted] [redacted] [redacted]
N/A N18272 001
JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA
DRAXIMAGE N/A N18489 001
OCT 31, 1986
[redacted] [redacted] [redacted]

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT
AP DRAXIMAGE N/A N18035 001
[redacted] [redacted] [redacted]

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA
AP DRAXIMAGE N/A N18511 001
DEC 29, 1989
[redacted] [redacted] [redacted]

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
AM-SULFUR COLLOID
AP CIS N/A N17858 001
[redacted]
[redacted] [redacted] [redacted]

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
[redacted]
◆ BRACCO N/A N16923 001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN
AB ABBOTT EQ 1MG BASE N20347 001
DEC 14, 1994
AB ◆ EQ 2MG BASE N20347 002
DEC 14, 1994
AB EQ 5MG BASE N20347 003
DEC 14, 1994
AB EQ 10MG BASE N20347 004
DEC 14, 1994
TERAZOSIN HCL
AB GENEVA PHARMS EQ 1MG BASE N74823 001
MAR 30, 1998
AB EQ 2MG BASE N74823 002
MAR 30, 1998
AB EQ 5MG BASE N74823 003
MAR 30, 1998
AB EQ 10MG BASE N74823 004
MAR 30, 1998

TERBINAFINE

GEL; TOPICAL
LAMISIL
◆ NOVARTIS 1% N20846 001
APR 29, 1998

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM
[redacted] [redacted] [redacted] [redacted]
◆ 2.5MG/24HR N20489 001
SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V
AB ESI LEDERLE 250MG N50278 003
AB ◆ [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]

TABLET; ORAL
SUMYCIN
ARCHIMICOM [redacted] [redacted]
[redacted] [redacted] [redacted]
● 50MG N61147 003
● 100MG N61147 002

THALIDOMIDE

CAPSULE; ORAL
THALOMID
◆ CELGENE 50MG N20785 001
JUL 16, 1998

THEOPHYLLINE

[redacted] [redacted]
[redacted] [redacted]
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
● 100MG N85545 001
JUL 31, 1984
● 200MG N83921 001
JUL 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL
[redacted] [redacted]
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
● 125MG N86826 001
JAN 29, 1985
● 250MG N86826 002
JAN 29, 1985

THEOPHYLLINE

TABLET; ORAL
QUIBRON-T
◆ MONARCH PHARMS 300MG N88656 001
AUG 22, 1985
[redacted] [redacted] [redacted] [redacted]

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR
[redacted] [redacted] [redacted] [redacted]
BC MONARCH PHARMS 300MG N87563 001
JUN 21, 1983

THIAMYLAL SODIUM

[redacted] [redacted]
[redacted] [redacted]
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
● PARKEDALE 1GM/VIAL N07600 003
● 5GM/VIAL N07600 005
● 10GM/VIAL N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL
AA PHARM ASSOC 100MG/ML N40213 001
MAY 29, 1998

TABLET; ORAL
THIORIDAZINE HCL
[redacted] [redacted] [redacted] [redacted]
● 25MG N88755 001
JUL 24, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID
● ROCHE 125MG N19979 001
MAR 24, 1993

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID
+ ROCHE 250MG N19979 002 OCT 31, 1991
[redacted]

TIMOLOL MALEATE

TABLET; ORAL
BLOCADREN
AB MERCK [redacted] N18017 001
AB [redacted] N18017 002
AB + [redacted] N18017 004
[redacted]

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT
+ MERCK EQ 0.05MG BASE/ML N20913 001 MAY 14, 1998
+ EQ 0.25MG BASE/ML N20912 001 MAY 14, 1998

TOLCAPONE

TABLET; ORAL
TASMAR
ROCHE 100MG N20697 001 JAN 29, 1998
+ 200MG N20697 002 JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL
DETROL
PHARMACIA AND UPJOHN 1MG N20771 001 MAR 25, 1998
+ PHARMACIA AND UPJOHN 2MG N20771 002 MAR 25, 1998

TORSEMIDE

INJECTABLE; INJECTION
DEMADEX
[redacted]
+ ROCHE 10MG/ML N20137 002 AUG 23, 1993

TABLET; ORAL
DEMADEX
[redacted]
ROCHE 5MG N20136 001 AUG 23, 1993
10MG N20136 002 AUG 23, 1993
20MG N20136 003 AUG 23, 1993
+ 100MG N20136 004 AUG 23, 1993

TRETINOIN

CREAM; TOPICAL
AVITA
[redacted]
AB 0.025% N20404 003 JAN 14, 1997

GEL; TOPICAL
AVITA
BT PENEDERM 0.025% N20400 001 JAN 29, 1998

TRETINOIN

GEL; TOPICAL
AVITA

RX	[redacted]	[redacted]	[redacted]	
				JAN 29, 1998

RETIN-A

	[redacted]	[redacted]	[redacted]	
RX	+ JOHNSON AND JOHNSON	0.025%	N17579 002	

SOLUTION; TOPICAL
RETIN-A

	[redacted]	[redacted]	[redacted]	
AT	+ JOHNSON AND JOHNSON	0.05%	N16921 001	

TRETINOIN

AT	COPLEY PHARM	0.05%	N74873 001	
				JUN 19, 1998

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

	● ALPHARMA	0.025%	N87797 001	
				JUN 07, 1982
RX	[redacted]	[redacted]	[redacted]	
				JUN 07, 1982

TRIAMCINOLONE DIACETATE

SYRUP; ORAL
[redacted]

	[redacted]	[redacted]	[redacted]	
	●	EQ 4MG BASE/5ML	N12515 001	

TRICHLORMETHIAZIDE

TABLET; ORAL
TRICHLORMETHIAZIDE

> DLT >	RX [redacted]	[redacted]	[redacted]	
> DLT >	RX [redacted]	[redacted]	[redacted]	
> ADD >	●	2MG	N83847 001	
> ADD >	●	4MG	N83855 001	

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	ZENITH GOLDLINE	EQ 1MG BASE	N87612 001	
				NOV 19, 1982
AB		EQ 2MG BASE	N87613 001	
				NOV 19, 1982
RX	[redacted]	[redacted]	[redacted]	
				[redacted]
RX		[redacted]	[redacted]	
				[redacted]

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
VIROPTIC

RX	[redacted]	1%	[redacted]	
AT	+ MONARCH PHARMS	1%	N18299 001	

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	CIRCA	2MG	N40184 001	
				FEB 06, 1998
AA		5MG	N40184 002	
				FEB 06, 1998

TRIMEPRAZINE TARTRATE

[redacted]

	[redacted]	[redacted]	[redacted]	
	●	EQ 5MG BASE	N11316 004	

[redacted]

	[redacted]	[redacted]	[redacted]	
	●	EQ 2.5MG BASE/5ML	N11316 003	

[redacted]

	[redacted]	[redacted]	[redacted]	
	●	EQ 2.5MG BASE	N11316 001	

TRIMETHAPHAN CAMSYLATE

[redacted]				
[redacted]				
●		50MG/ML		N08983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TIGAN

AP	◆	ROBERTS LABS	100MG/ML	N17530 001
[redacted]				

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM

[redacted]				
[redacted]				
AB		MONARCH PHARMS	100MG	N17943 001
AB	◆		200MG	N17943 003
				JUL 14, 1982

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

	◆	US BIOSCIENCE	EQ 200MG BASE/VIAL	N20326 002
				JUL 31, 1998

TROGLITAZONE

TABLET; ORAL
REZULIN

[redacted]				
[redacted]				
[redacted]				
AB		PARKE DAVIS PHARMS	200MG	N20720 003
				JAN 29, 1997

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

TROGLITAZONE

TABLET; ORAL
REZULIN

AB		PARKE DAVIS PHARMS	300MG	N20720 003
				AUG 04, 1997
AB			400MG	N20720 002
				JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

[redacted]				
[redacted]				
	●		1%	N88447 001
				AUG 28, 1985

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX

	◆	SERONO	75 IU/AMP	N19415 002
				SEP 18, 1986
	◆		150 IU/AMP	N19415 003
				SEP 18, 1986
[redacted]				
[redacted]				
	◆		75 IU/AMP	N19415 002
				SEP 18, 1986
	◆		150 IU/AMP	N19415 003
				SEP 18, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE

	◆	ANTHRA	40MG/ML	N20892 001
				SEP 25, 1998

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

	◆	ELAN	120MG	N19614 001
				MAY 29, 1990

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

> ADD >	+	ELAN	180MG	N19614 003 JAN 09, 1992
> ADD >	+		240MG	N19614 002 MAY 29, 1990
> ADD >	+		360MG	N19614 004 [illegible]
> DLT >	#	[illegible]	[illegible]	[illegible]
> DLT >	#		[illegible]	[illegible]
> DLT >	#		[illegible]	[illegible]
> DLT >	#		[illegible]	[illegible]
> DLT >	#		[illegible]	[illegible]

INJECTABLE; INJECTION
VERAPAMIL HCL

AP	[illegible]	[illegible]	[illegible]
AP		[illegible]	[illegible]
	●	2.5MG/ML	N72233 001 FEB 26, 1993
	●	2.5MG/ML	N73485 001 SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION
VIRA-A

	#	[illegible]	EQ 187.4MG BASE/ML	[illegible]
	●	PARKEDALE	EQ 187.4MG BASE/ML	N50523 001

OINTMENT; OPHTHALMIC
VIRA-A

	#	[illegible]	3%	[illegible]
	+	PARKEDALE	3%	N50486 001

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

> DLT >	#	[illegible]	[illegible]	[illegible]
> DLT >	#	[illegible]	[illegible]	[illegible]
> DLT >	#	[illegible]	[illegible]	[illegible]

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

> DLT >	#	[illegible]	[illegible]	[illegible]
> DLT >	#	[illegible]	[illegible]	[illegible]
> DLT >	#	[illegible]	[illegible]	[illegible]
> DLT >				
> ADD >	●		1MG/VIAL	N71559 001 APR 11, 1988
> ADD >				
> ADD >	●		2MG/VIAL	N71560 001 APR 11, 1988
> ADD >				
> ADD >	●		5MG/VIAL	N71561 001 APR 11, 1988
> ADD >				

WATER FOR INJECTION, STERILE

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP		B BRAUN	100%	N19633 001 FEB 29, 1988
AP		[illegible]	[illegible]	[illegible]

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
EXCEDRIN (MIGRAINE)
+ BRISTOL MYERS — 250MG;250MG;65MG — N20802 001 JAN 14, 1998

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
GAVISCON
[redacted] — [redacted] — [redacted]
80MG;20MG — N18685 001 DEC 09, 1983
+ 160MG;40MG — N18685 002 DEC 09, 1983

GAVISCON-2
[redacted] — [redacted] — [redacted]

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
CHG SCRUB
ECOLAB — 4% — N19258 002 JUL 22, 1986
[redacted] — [redacted] — [redacted]

CIDA-STAT
ECOLAB — 2% — N19258 001 JUL 22, 1986
[redacted] — [redacted] — [redacted]

CIMETIDINE

TABLET; ORAL
CIMETIDINE
LEK PHARM — 100MG — N75122 001 JUN 19, 1998
200MG — N75122 002 JUN 19, 1998
NOVOPHARM — 200MG — N74961 001 JUN 19, 1998

> ADD >
> ADD >
> ADD >
> ADD >

CIMETIDINE

TABLET; ORAL
CIMETIDINE
PERRIGO — 100MG — N74972 001 JUN 19, 1998
PHARM FORM — 200MG — N74963 001 JUN 19, 1998
TORPHARM — 100MG — N74948 001 JUN 19, 1998

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX
COPLEY PHARM — 100MG — N73249 001 FEB 13, 1998

FAMOTIDINE

TABLET, CHEWABLE; ORAL
PEPCID AC
+ MERCK — 10MG — N20801 001 SEP 24, 1998

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED
[redacted] — [redacted] — [redacted]
100MG/5ML — N20589 002 NOV 07, 1997

SUSPENSION/DROPS; ORAL
PEDIATRIC ADVIL
+ WHITEHALL ROBINS — 100MG/2.5ML — N20812 001 JAN 30, 1998

TABLET; ORAL
IBUPRIN
[redacted] — [redacted] — [redacted]
● — 200MG — N71773 001 JUL 16, 1987

IBUPROFEN

TABLET; ORAL
IBUPROFEN

> DLT >		[redacted]	[redacted]	[redacted]
> DLT >				[redacted]
> ADD >			200MG	N71905 001
> ADD >				MAR 08, 1988
> DLT >		[redacted]	[redacted]	[redacted]
> DLT >				[redacted]
> ADD >			200MG	N73019 001
> ADD >				MAR 30, 1994
		NOVOPHARM	200MG	N74931 001
				JUL 20, 1998
		PHARM FORM	200MG	N74782 001
				JUL 06, 1998
		[redacted]		
		[redacted]	[redacted]	[redacted]
				[redacted]
			[redacted]	[redacted]
				[redacted]
		[redacted]	200MG	N72035 001
				FEB 16, 1988
		[redacted]	200MG	N72036 001
				FEB 16, 1988
> DLT >		[redacted]	[redacted]	[redacted]
> DLT >				[redacted]
		[redacted]	[redacted]	[redacted]
				[redacted]
> ADD >		[redacted]	200MG	N19012 001
> ADD >				MAY 18, 1984
			200MG	N19012 003
				JUL 29, 1987

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN

		[redacted]	[redacted]	[redacted]
				[redacted]
		[redacted]	100MG	N20601 003
				NOV 15, 1996

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN R PEN

		+ LILLY	100 UNITS/ML	N18780 005
				AUG 06, 1998

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN 70/30 PEN

		+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 002
				AUG 06, 1998

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3

		+ ADVANCED CARE PRODS	4%	N20827 001
				MAR 30, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

		NOVEX	2%	N74924 001
				APR 29, 1998
		[redacted]	[redacted]	[redacted]
				[redacted]

MINOXIDIL (FOR WOMEN)

		NOVEX	2%	N74924 002
				APR 29, 1998
		[redacted]	[redacted]	[redacted]
				[redacted]

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

		PAR PHARM	EQ 200MG BASE	N75168 001
				JUL 28, 1998

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL

		[redacted]	[redacted]	[redacted]
				[redacted]
		+ PHARMACIA AND UPJOHN	15MG/16HR	N20536 001
				JUL 03, 1996

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75
+ GLAXO WELLCOME EQ 75MG BASE N20745 001
FEB 26, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 9 SEP '98

NO SEPTEMBER 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/29/1998
3-(3,5-dimethyl-1H-2ylmethylene) -1,3-dihydro-indol-2-one TN=	Treatment of Kaposi's sarcoma.	Sugen, Inc. 230 East Grand Ave. South San Francisco, CA 94080 DD=09/11/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Aldesleukin TN= Proleukin	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=07/31/1998
Aliperetinate TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Alpha-galactosidase A TN=	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge, MA 02139 DD=06/22/1998
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DL=02/03/1998
Botulinum toxin type A TN= Dysport	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road Maidenhead, Berkshire U.K. SL6 4UH DD=08/12/1998
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France, DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dexamethasone TN=	For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.	Oculex Pharmaceuticals 639 N. Pastoria Avenue Sunnyvale, CA 94086 DD=09/11/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Fructose-1,6-diphosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998
Humanized anti-human CD2 MAb TN= MEDI-507	For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.	Biotransplant, Inc. Building 75, 3rd. Ave. Charlestown Navy Yard Charlestown, MA 02129 DD=09/17/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998
Infliximab TN= Remicade	Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).	Centocor, Inc. 200 Great Valley Parkway Malvern, PA 19355 DD=11/14/1995 MA=08/24/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience, Inc. 8400 Darnley Road Montreal, Quebec Canada H4T 1M4 DD=01/06/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Lamotrigine TN= Lamictal	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development 5 Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=08/23/1995 MA=08/24/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Liposomal N-Acetylglucosmi nyl-N-Acetylmura mly-L-Ala-D-isoG ln-L-Ala -gylcerolidpalmi toyl TN= ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
Liposomal N-Acetylglucosmi nyl-N-Acetylmura mly-L-Ala-D-isoG ln-L-Ala -gylcerolidpalmi toyl TN= ImmTher	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
MN14 monoclonal antibody to carcinoembryonic antigen TN= CEA-CIDE	For the treatment of small cell lung cancer.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=09/18/1998
Mafenide acetate solution TN= Sulfamylon solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504 DD=07/18/1990 MA=06/05/1998
Octreotide TN= Sandostatin LAR	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Octreotide TN= Sandostatin LAR	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Octreotide TN= Sandostatin LAR	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
PEGASYS TN=	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=07/13/1998
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles, CA 90032 DD=06/12/1998
Radiolabeled monoclonal antibody to CD22 antigen on B-cells TN= LymphoCIDE	Treatment of non-Hodgkin's lymphoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=07/13/1998
Recombinant bactericidal/permeability-increasing protein TN= Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley, CA 94710 DD=06/22/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human Clara Cell 10kDa protein TN=	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park, MD 20742 DD=07/13/1998
Recombinant humanized monclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifapentine TN= Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Mail Station: H3-M2516 Kansas City, MO 64134 DD=06/09/1995 MA=06/22/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Care Center Philips Building, Suite 2Q; 10 Union Square East New York, NY 10003 DD=04/30/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Tetrabenazine TN=	Treatment of moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England DD=05/12/1998
Thalidomide TN= Thalomid	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=07/26/1995 MA=07/16/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998

Orphan Product Designations and Approvals List
January 1998 through September 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Thalidomide TN=	Treatment of Kaposi's sarcoma.	EntreMed, Inc. 9610 Medical Center Dr., Suite 200 Rockville, MD 20850 DD=07/29/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998
Valrubicin TN= Valstar	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 Princeton, NJ 08540 DD=05/23/1994 MA=09/25/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ABBREVIATIONS

PED	PEDIATRIC EXCLUSIVITY

REFERENCES

NEW DOSING *SCHEDULE*

D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	TAKE DRUG "15 MINUTES TO 1 HOUR" PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN
D-48	ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES

NEW INDICATION

I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (Ccr 15 TO 55ML MIN) NOT YET ON DIALYSIS
I-241	
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020482	006	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
			5731296	MAR 24, 2015	U-221		
020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5766573	JUN 16, 2015		I-235	SEP 23, 2001
020560	001	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
020560	002	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
020560	003	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
020511	001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243		
019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
020304	001	APROTININ BOVINE;TRASYLOL				I-233	AUG 28, 2001
020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
			5234404	AUG 10, 2010	U-220		
			5395970	MAR 07, 2012			
020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
						I-219	JUL 10, 2001
020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
						I-219	JUL 10, 2001
020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
						I-219	JUL 10, 2001
020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	OCT 16, 2011	U-207		
018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4689070	MAY 13, 2003			
020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
			5378703	AUG 31, 2010	U-226		
			5461081	OCT 24, 2012	U-225		
020441	002	BUDESONIDE;PULMICORT				D-45	OCT 08, 2001
>ADD> 020358	001	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
>ADD>			5731000	AUG 12, 2013			
>ADD> 020358	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
>ADD>			5731000	AUG 12, 2013			
>ADD> 020358	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5731000	AUG 12, 2013			
>ADD>			5763493	AUG 12, 2013			
020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177		
020554	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
>ADD> 018044	001	CALCITRIOL;ROCALTROL				I-240	NOV 20, 2001
>ADD> 021068	001	CALCITRIOL;ROCALTROL				NDF	NOV 20, 2001
>ADD>						I-240	NOV 20, 2001
020521	001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
020838	001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011			
			5705517	APR 18, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020838	002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
>ADD>	019972	001	CARTEOLOL HYDROCHLORIDE;OCUPRESS	4309432	JAN 02, 2000			
	020297	001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020774	001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
	020238	002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
	020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
	020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
				4844902	FEB 11, 2008			
>ADD>	019847	001	CIPROFLOXACIN;CIPRO				I-164	SEP 11, 1999
>ADD>							I-245	JUN 03, 2000
	020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
>ADD>	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-164	SEP 11, 1999
>ADD>							I-245	JUN 03, 2000
>ADD>	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%				I-164	SEP 11, 1999
>ADD>							I-245	JUN 03, 2000
>ADD>	020551	001	CISATRACURIUM BESYLATE;NIMBEX				D-48	OCT 15, 2001
>ADD>	020551	002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE				D-48	OCT 15, 2001
>ADD>	020551	003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE				D-48	OCT 15, 2001
	020822	002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020839	001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
018938	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
018938	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
019955	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
019955	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
020713	001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
020344	001	DEXFENFLURAMINE HYDROCHLORIDE;REDUX	4309445	FEB 19, 2004	U-133		
020809	001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
			5653972	NOV 16, 2014	U-239		
020037	001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
			4462983	JUL 31, 2001	U-227		
			5169849	DEC 08, 2009			
					U-227		
020401	001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401	002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401	003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401	004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401	005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020449	001	DOCETAXEL;TAXOTERE				I-231	JUN 22, 2001
020690	001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
020690	002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
020869	001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
020972	001	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
020972	002	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
020972	003	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
020164	001	ENOXAPARIN SODIUM;LOVENOX				I-217	JAN 30, 2001
						I-222	MAR 27, 2001
020164	002	ENOXAPARIN SODIUM;LOVENOX				I-222	MAR 27, 2001
						I-217	JAN 30, 2001
020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
020718	001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
			5686570	NOV 11, 2014			
			5807825	SEP 15, 2015	U-244		
020718	002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
			5686570	NOV 11, 2014			
			5807825	SEP 15, 2015	U-244		
>ADD> >ADD>	020907	001 ESTRADIOL;ACTIVELLE				NC	NOV 18, 2001
						I-242	NOV 18, 2001
020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020870	001	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
020870	002	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
020527	002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
020527	001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
020363	001	FAMCICLOVIR;FAMVIR				NCE	JUN 29, 1999
						I-232	JUN 12, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020363	002	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
	020363	003	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
>ADD>	020325	001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
>ADD>	019510	004	FAMOTIDINE;PEPCID PRESERVATIVE FREE	4283408	OCT 15, 2000			
	020752	001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020752	002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	4254129	FEB 18, 2001	U-139		
	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	FEB 18, 2001		NCE	JUL 25, 2001
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			
	020788	001	FINASTERIDE;PROPECIA	5547957	OCT 15, 2013	U-236		
	020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
	018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018554	001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
				5712251	SEP 18, 2001	U-216		
	020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
	020378	001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			
	020378	002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			
	020961	001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
	020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003			
	020235	001	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
	020235	002	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
	020235	003	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
	020882	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
				4894476	MAY 02, 2008			
				5084479	JAN 02, 2010			
	020882	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
				4894476	MAY 02, 2008			
				5084479	JAN 02, 2010			
	019596	001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5560903	OCT 01, 2013			
	020460	001	GANCICLOVIR;CYTOVENE	4423050	MAY 21, 2001	U-64		
				4642346	JUN 24, 2005			
				4507305	MAY 12, 2001	U-64		
	020509	001	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
	020509	002	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
	020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
	016295	002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	019771	001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	NOV 12, 2002			
				4552899*PED	MAY 12, 2003			
	019833	002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
				4788220*PED	MAY 29, 2006			
	020589	001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
				4788220*PED	JAN 08, 2008		PED	DEC 16, 1998
	020516	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
	020601	001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
	020603	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
	020601	003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
	020602	001	IBUPROFEN;JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
							PED	DEC 16, 1998
	019842	001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
				5374659*PED	JUN 20, 2012			
	020135	001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020135	002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
	020903	001	INTERFERON ALFA-2B;REBETRON	4530901	JUL 23, 2002		NP	JUN 03, 2001
				4211771	JUL 08, 1999	U-234		
				5767097	JAN 23, 2016	U-235		
	020923	001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
	020923	002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
	020923	003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
>ADD>	020394	001	IPRATROPIUM BROMIDE;ATROVENT				I-243	NOV 09, 2001
	020571	001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007			
	020083	001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
	020657	001	ITRACONAZOLE;SPORANOX	4267179	JUN 23, 2000			
				5707975	JAN 13, 2015			
				4727064	FEB 23, 2005			
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
	020310	001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245		
				4335125	JUN 15, 1999			
				5456851	APR 07, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020241	001	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	002	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	003	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	004	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	005	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	006	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020764	001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
			4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
020764	002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
			4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
020764	003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
			4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
020406	001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
						D-42	JUL 20, 2001
020406	002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
						D-42	JUL 20, 2001
>ADD> 020905	001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
>ADD>			4351841	DEC 13, 1999	U-247		
>ADD>			5679709	OCT 21, 2014	U-247		
>ADD> 020905	002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
>ADD>			4351841	DEC 13, 1999	U-247		
>ADD>			5679709	OCT 21, 2014	U-247		
>ADD> 020905	003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
>ADD>			4351841	DEC 13, 1999	U-247		
>ADD>			5679709	OCT 21, 2014	U-247		
020807	001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
						NCE	MAR 06, 2003
019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020263	002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
020517	002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
019941	001	LIDOCAINE;EMLA				I-215	FEB 04, 2001
020962	001	LIDOCAINE;EMLA				NP	FEB 04, 2001
020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5716641	MAY 21, 2012	U-226		
020803	001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
			5540930	OCT 25, 2013			
020583	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
			5540930	OCT 25, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	019832	003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
							ODE	JUN 05, 2005
	020652	001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007			
				4992554	FEB 12, 2008			
				5091169	FEB 25, 2009			
				5223243	JUN 29, 2010	U-237		
				4647447	MAR 03, 2004	U-238		
	019618	001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
				RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000
>ADD>	020901	001	METRONIDAZOLE;METROLOTION				NDF	NOV 24, 2001
	020827	001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001
	018654	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
				4280957*PED	JUN 20, 2000			
	018654	002	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
				4280957*PED	JUN 20, 2000			
>ADD>	020942	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999		PED	APR 15, 2002
>ADD>				4280957*PED	JUN 20, 2000		NDF	OCT 15, 2001
	020415	003	MIRTAZAPINE;REMERON				NCE	JUN 14, 2001
	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001			
	020829	002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020830	001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
>ADD>	020636	001	NEVIRAPINE;VIRAMUNE				D-49	SEP 11, 2001
	020933	001	NEVIRAPINE;VIRAMUNE				NDF	SEP 11, 2001
							NCE	JUN 21, 2001
	020536	001	NICOTINE;NICOTROL	4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR				I-220	APR 01, 2001
							D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN				NDF	DEC 16, 2000
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	5116863	DEC 18, 2010			
	019810	001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	019810	002	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
>ADD>	020932	002	OXYCODONE HYDROCHLORIDE;ROXICODONE				NS	OCT 26, 2001
	020262	001	PACLITAXEL;TAXOL				I-226	APR 09, 2001
							I-230	JUN 30, 2001
	020819	001	PARICALCITOL;ZEMPLAR				NCE	APR 17, 2003
	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	5811436	SEP 22, 2015			
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
							I-212	FEB 11, 2001
	020431	001	PORFIMER SODIUM;PHOTOFRIN	5145863	DEC 15, 2009	U-129		
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
			4843086	JUN 27, 2006	U-231		
020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
			4843086	JUN 27, 2006	U-231		
019898	002	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
019898	003	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
019898	004	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
019781	001	PROGESTERONE;PROMETRIUM				NP	MAY 14, 2001
019627	002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217		
			5731356	MAR 22, 2015	U-218		
020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001			
			5393763	JUL 28, 2012	U-114		
			5457117	JUL 28, 2012	U-114		
			5478847	MAR 02, 2014	U-114		
020520	001	RANITIDINE HYDROCHLORIDE;ZANTAC 75				I-228	JUN 08, 2001
021024	001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
						ODE	JUN 22, 2005
020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
020864	001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
			5602162	MAY 10, 2015	U-240		
020864	002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
			5602162	MAY 10, 2015	U-240		
020865	001	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
			5298520	JAN 28, 2012	U-240		
			4758598	DEC 15, 1998			
			4371516	FEB 01, 2000			
			5602162	MAY 10, 2015	U-240		
020865	002	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
			5298520	JAN 28, 2012	U-240		
			4758598	DEC 15, 1998			
			4371516	FEB 01, 2000			
			5602162	MAY 10, 2015	U-240		
020533	001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020533	003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020533	004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020533	005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
						NCE	APR 09, 2003
020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211	I-237	SEP 25, 2001
			5380922	JAN 10, 2012		I-236	SEP 25, 2001
			5590645	MAR 01, 2011			
			5126375	FEB 12, 2008			
			D342994	JAN 04, 2008			
020828	001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2012			
020443	001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
			4703035	DEC 28, 2004			
020443	002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
			4703035	DEC 28, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020926	001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
>ADD>				5667775	SEP 16, 2014	U-246		
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
>ADD>	020773	001	SIMETHICONE-CELLULOSE;SONORX				NP	OCT 29, 2001
	019766	001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005		NS	JUL 10, 2001
							I-239	JUL 10, 2001
							D-46	JUL 10, 2001
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
	020626	001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	003	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
>ADD>	017970	001	TAMOXIFEN CITRATE;NOLVADEX				I-244	OCT 29, 2001
>ADD>	017970	002	TAMOXIFEN CITRATE;NOLVADEX				I-244	OCT 29, 2001
>ADD>	020887	001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
>ADD>				5645815	JUL 08, 2014			
>ADD>				5443815	AUG 22, 2012			
>ADD>	020850	001	TELMISARTAN;MICARDIS				NCE	NOV 10, 2003
>ADD>	020850	002	TELMISARTAN;MICARDIS				NCE	NOV 10, 2003
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
	020785	001	THALIDOMIDE;THALOMID				NCE	JUL 16, 2003
							ODE	JUL 16, 2005
	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
>ADD>	020844	001	TOPIRAMATE;TOPAMAX SPRINKLE				NCE	DEC 24, 2001
>ADD>	020844	002	TOPIRAMATE;TOPAMAX SPRINKLE				NCE	DEC 24, 2001
>ADD>	020844	003	TOPIRAMATE;TOPAMAX SPRINKLE				NCE	DEC 24, 2001
	020671	001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
	020281	001	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
	020281	002	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020719	001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020719	002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020719	003	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020720	001	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020720	002	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020720	003	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020586	001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147		
	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			
	020892	001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
							CDE	SEP 25, 2005
	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020388	001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
	020547	001	ZAFIRLUKAST;ACCOLATE	4859692	SEP 27, 2010			
	020471	001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		

*U.S. Government Printing Office: 1998 — 454-723/00003

New 19th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
*** 8240**

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

— subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $78.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account [ ] – [ ]
☐ VISA or MasterCard
[ ]

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( ) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature) (10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
6"